Posts by acn:

The 18th Annual Global CSR & ESG Summit & Awards 2026 Arrives in Bangkok — Igniting Asia with AI, Energy & ESG Innovation on 23 April 2026

SINGAPORE, Feb 11, 2026 - (ACN Newswire via SeaPRwire.com) - Asia’s longest-running sustainability event is coming to Bangkok. On 23 April 2026, the 18th Annual Global CSR & ESG Summit & Awards 2026 lands in Thailand’s vibrant capital, bringing together global leaders, innovators, and changemakers for a high-energy, future-focused gathering that redefines what a sustainability summit can be.Guided by the theme “AI, Energy & Transition: Resetting ESG in a New Economy,” this flagship Summit reimagines the traditional conference into an immersive, high-impact experience—bringing together innovation, leadership, and purpose on one dynamic stage.More than a conference, the Summit combines visionary discussions with inspiring award moments, exploring sustainability in an era shaped by AI, energy transition, and geopolitical change. Through immersive presentations, thought-provoking panels, and four integrated award segments, participants will examine how these forces are reshaping corporate responsibility—and whether ESG is evolving fast enough for a digitised, energy-hungry world.The refreshed format blends insight with inspiration, featuring cinematic storytelling, live performances, and real-world case studies that spotlight purpose-driven leadership and transformational impact.With over 60 companies already confirmed from across Asia and beyond, momentum is strong.Organisations are also invited to participate in the 18th Annual Global CSR & ESG Awards™️ 2026, recognising initiatives that demonstrate measurable impact, strong governance, and strategic foresight.Award Categories Include:- Best Environmental Excellence Award- Best Community Programme Award- Excellence in Provision of Literacy & Education Award- Empowerment of Women Award- Best Workplace Practices- Product Excellence Award- CSR & ESG Leadership Award- Best CEO | Best CFO- Best Corporate Communications & Investor Relations TeamBest Country Awards: Singapore | Malaysia | Thailand | Philippines | India | Indonesia | Cambodia | Vietnam | Middle EastAs ESG expectations rise, the Summit offers a timely platform for meaningful dialogue, practical insights, and recognition of credible initiatives—set against the vibrant backdrop of Bangkok.Join us to ignite action, celebrate excellence, and help redefine ESG for a rapidly changing global economy.For more information visit the official Website: https://globalcsr.pinnaclegroup.global/For Media Inquiries:Eric KhooConference Director18th Annual Global CSR & ESG Summit & Awards™️eric.khoo@pinnaclegroup.globalHDP / WhatsApp: +65 8383 2480 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Kincora and AngloGold Ashanti Exploration Expands and Upgrades Nevertire with Drilling Recommenced

Melbourne, Australia--(ACN Newswire via SeaPRwire.com - February 10, 2026) - Copper-gold explorer and hybrid prospect generator Kincora Copper Limited (ASX: KCC) (TSXV: KCC) (Kincora or the Company) is pleased to provide an update on strong initial results and an acceleration of exploration activities following completion of the Phase 1 drilling program at the Nevertire and Nevertire-South projects. The programs are being conducted under earn-in and joint venture agreements with AngloGold Ashanti Australia Limited (AngloGold Ashanti).Phase 1 drilling has upgraded the immediate target zone and reaffirmed Kincora's view that the Nevertire Magmatic Complex (NMC) represents the most advanced and geologically prospective porphyry project within the covered northern extensions of the Macquarie Arc. Drilling has now recommenced to follow up high-priority targets advanced during the second half of 2025.In parallel, exploration activities have expanded to materially increase the search space to the south of the NMC. New geophysical surveys and a review of prior explorer drilling are underway to systematically evaluate and advance a prospective strike length exceeding 40km across the Nevertire and Nevertire South licenses.HIGHLIGHTSExtensive porphyry complex with multiple discovery potential confirmed: Phase 1 drilling (8-holes for 3385.2 metres, completed in 2H'2025) validated the presence of a large, highly prospective composite volcanic-intrusive complex across a greater than 5.4km strike at the Nevertire Magmatic Complex (NMC). Drilling intesected porphyry related lithologies, alteration, and vein hosted and disseminated copper, gold and pathfinder mineralisation.Targets upgraded; follow-up drilling underway: Phase 1 successfully upgraded the immediate target zone (open in all directions) and generated strong vectors for follow-up drilling. Copper and gold grades suggest increasing proximity to one or more porphyry system centre(s) (Figure 5). High-priority infill and step-out drilling has recommenced to further refine vectoring patterns and test multiple potential porphyry centres.Scale increased to province-scale: Phase 1 results combined with a review of prior explorer drilling support a greater than six-fold increase in the prospective strike length across the Nevertire and Nevertire South licenses. An initial ~110km² gravity surveying has been completed as part of a planned ~400km² program. The results, together with historical core resampling, are expected to refine step-out and scout drilling targets across multiple newly interpreted Macquarie Arc intrusive complexes.Expanded scout drilling planned at Nyngan: Planning and permitting are underway to expand scout drilling at two targets at the Nyngan license along with a potential first-ever hole at the adjacent Nyngan South license.Strong partnership and commercial alignment: The Nyngan, Nyngan South, Nevertire South and Nevertire projects form part of two earn-in and joint venture agreements with AngloGold Ashanti, which has the right to invest up to A$100-million across a total of five projects covering a continuous strike greater than 100km within Kincora's Northern Junee-Narromine Belt (NJNB) portfolio. Kincora currently manages the programs and receives a 10% management fee on expenditures.John Holliday, Technical Committee chair, and Peter Leaman, VP of Exploration, said:"Initial results have been very positive, validating Newcrest's prior analogues to the Cadia-Ridgeway and the Goonumbla (Northparkes) porphyry deposits and reaffirmed our view that the Nevertire Magmatic Complex is the most advanced and prospective porphyry project in the covered northern extensions of the Macquarie Arc. As a result, activities have been expanded to both follow up immediate high priority targets with drilling but also systematically advance a province-scale pipeline across a greater than 40km strike. Phase 1 drilling included large step-out holes from two previously favourable Newcrest intercepts and successfully upgraded the immediate target zone. We are very excited to have recommenced drilling, as the results indicate a new, large-scale mineralised system with the geological characteristics required for multiple discoveries.Additional scale is also emerging to the south. A review of prior explorer drilling and a ground gravity survey completed in late 2025 have highlighted significant southern extension potential, where favourable basement intersections, anomalous results, and untested magnetic and gravity anomalies remain open for drill testing.Separately, planning continues to support further scout drilling at the Nyngan and potentially Nyngan South projects. With a portfolio exceeding 2,350km² and a strong partnership with AngloGold Ashanti, Kincora is well positioned to systematically advance this unique, province-scale opportunity, offering substantial leverage to shareholders."NEVERTIRE AND NEVERTIRE SOUTH PROJECTSTarget specific drilling Following the April 2025 amended and second earn-in agreement with AngloGold Ashanti 1, a first phase drilling program commenced at both the Nevertire and Nevertire South licenses in 2H'2025. The program benefitied from unimpeded access across the consolidated ~8 x 12km Nevertire Magmatic Complex (NMC) and was designed to follow up two prior favourable drill results reported by Newcrest Mining and the most northern drilled holes at the NMC.Newcrest holes ACDNY005 and ACDNY006 were drilled ~2.7km apart, in the central portion of the NMC, and returned "lithologies, alteration and veining consistent with a setting similar to the Cadia-Ridgeway and Goonumbla (Northparkes) porphyry Cu-Au deposits" 2. Kincora's relogging of these holes, led by technical director John Holliday, supported this interpretation.The Phase 1 program included large scale step-out drilling and was designed to identify and define vectoring patterns toward potential porphyry centres. This program was very encouraging in providing strong vectors, upgrading the immediate target zone, supporting Newcrest's previous interpretation and reaffirming the Company's view that the NMC is the most geologically prospective porphyry project in the northern covered extensions of the Macquarie Arc.The 8 hole program, totalling 3385.2 metres, utilised cost-effective mud-rotary drilling through the relatively soft post mineral cover sequence, followed by NQ3 diamond core drilling of the porphyry-prospective basement. All holes intersected basement. Drilling to date has intersected the NMC at shallow to moderate depths, with basement mostly at ~70m (in the south-west) to a 250m depth.Step-out drilling across a greater than 4km of strike intersected multiple porphyritic intrusive phases beneath a moderate thickness of post-mineral cover - see Figures 4-5 and Tables 1-4. Lithologies intersected include monzonite, diorite, dacite, and crowded pyroxene-hornblende andesites - see selected core photographs in Figure 6. Favourable alteration and porphyry-style veining were observed, with copper, gold and pathfinder element geochemistry providing vectors for high-priority follow-up drilling, including copper grades suggestive of increasing proximity to a porphyry system centre(s) (see Figure 5).High priority infill and further step-out drilling has recommenced to discover and refine vectoring patterns toward prospective porphyry centres.Larger scale new target and intrusive complex generation As previously announced, following encouraging initial visual observations, follow-up geophysical surveys commenced in 2H'2025, together with a review of prior explorer drilling results and ground gravity survey data 3.These activities have resulted in a material increase in the prospective search space across the Nevertire and Nevertire South licenses, supporting a total prospective strike of greater than 40km N-S, representing a greater than 6x increase relative to the initial Phase 1 drill strike extent - see Figure 3.A gravity survey covering ~110km2 has been completed and is currently being intergrated with legacy gravity data-sets, totalling ~148km2, acquired by prior explorers. These historical surveys were variable in coverage density and spatial distribution, reflecting piecemeal target-specific objectives. When combined with the new systematic gravity coverage, the dataset is expected to support a more coherent district-scale interpretation, with a further ~290km² of gravity surveying planned in 2026.Prior explorer drilling across the southern extensions of the NMC includes 23 diamond holes totalling 7,383.7 metres, with some drillcore hosted in the publicly accessible Londonderry core library at the NSW Government's WB Clarke Geoscience Centre. Numerous historical drillholes in the Nevertire South priority area and adjacent southern targets were only partially sampled or analysed for a limited element suite, and most critical porphyry pathfinder elements were not consistently assayed.As a result, multiple historical drillholes intersecting basement, coincident with favourable magnetic and/or gravity anomalies and returning anomalous geochemical results, were not advanced beyond initial testing. Many of these intersections are now recognised to be spatially associated with interpreted Macquarie Arc intrusive complexes that remain open and untested.Resampling, re-logging and modern analytical work on high-priority historical drillholes, together with new geophysical data, is planned and is expected to expand and systematically advance the exploration pipeline, refine further step-out and scout drilling targets, and support evaluation of multiple potential new Macquarie Arc intrusive complexes.Figure 1: Kincora and AngloGold Ashanti have partnered to explore new district-scale undercover extensions of the world-class Macquarie Arc in the Northern Junee-Narromine Belt via two earn-in and joint venture agreements, currently aggressively drilling large greenfield targets Kincora has a portfolio of eight active projects, including managing two earn-in programs with AngloGold Ashanti, receiving a 10% management fee on expenditures, and covering a continuous 100km strike across 5 adjacent licenses (see References footnote 7 for source data for disclosed inventory/metal endowment)To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/2305/283322_9d387295a4fb3b48_001full.jpgFigure 2: Positive results have supported an acceleration of exploration activities, with step-out and infill drilling recommenced at the Nevertire South license, wider exploration planned to the south, and planning underway for recommencing drilling at multiple targets within the the Nyngan license, and potentially a maiden scout hole in the Nyngan South license To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/2305/283322_9d387295a4fb3b48_002full.jpgFigure 3: Phase 1 drilling results reaffirm Kincora's view that the NMC is the most advanced and geologically prospective porphyry project in the covered northern extensions of the Macquarie Arc, with the southern strike highlighting new province-scale potential A gravity survey covering >100 km² has been completed within a planned total survey area of >400 km². This work, together with resampling of historical drill core, is expected to refine step-out and scout drilling targets and support evaluation of multiple potentially new Macquarie Arc intrusive complex targets. Initial drilling has commenced with broad area approvals in place for upto 16 holes with further approvals to the south pending.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/2305/283322_9d387295a4fb3b48_003full.jpgFigure 4: Phase 1 drilling included large scale step out drilling across a >4km strike in the central to northern portions of the NMCPlan view of 2H'2025 drilling, with the corresponding long section provided in Figure 5. Results are consistent with Newcrest's prior interpretation that the project hosts lithologies, alteration and veining characteristic of a setting comparable to Macquarie Arc porphyry systems such as Cadia-Ridgeway and Goonumbla (Ridgeway) ²To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/2305/283322_9d387295a4fb3b48_004full.jpgFigure 5: Phase 1 drilling successfully upgraded the immediate target zone (open in all directions), providing vectors for follow up drilling, including copper and gold grades suggestive of proximity to a porphyry system centreInformation disclosed for Cadia-Ridgeway is not necessarily indicative of the Nevertire Magmatic Complex ("NMC"), and is provided for illustrative purposes only to demonstrate the typically discrete alteration and mineralisation footprints characteristic of Macquarie Arc "pencil" or "finger" porphyry systems. Phase 1 drilling by Kincora has returned encouraging copper and gold assay results, together with lithologies, alteration and veining consistent with this conceptual framework, supporting its relevance.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/2305/283322_9d387295a4fb3b48_005full.jpgFigure 6: Positive observations with intrusions, hydrothermal alteration, porphyry veining associated with disseminated and vein-hosted sulphideDetailed core photography of selection portions of 2H'2025 drilling, showing a range of mineralisation and alteration types from mineralised intervals within the middle-northern section of the Nevertire Magmatic Complex ("NMC")See Tables 1-3 for additional geological discriptions, peak and significant assay resultsFor Photos of the drill core please refer to the PDF of this release available on Kincora's home page at https://kincoracopper.com/wp-content/uploads/2026/02/20260210_KCC_Exploration-expands-and-upgrades-Nevertire-South.pdf(09-02-2026)Hole NEDD005 - 348.1m: stockwork chalcopyrite-pyrite bearing quartz-carbonate veins intersect silicified dacite porphyry, returning elevated copper (542 ppm) with minor zinc.Hole NEDD005 - 358.6m: stockwork chalcopyrite-pyrite bearing quartz-carbonate veins intersect silicified, brecciated dacite porphyry, returning elevated copper (235 ppm) with minor molybdenum and zinc.Hole NEDD006 - 337.15m: chalcopyrite-pyrite bearing quartz-carbonate veins cutting strongly propylitic altered intermediate volcanic rocks, returning elevated copper (4470 ppm) with minor gold, molybdenum, silver and zinc.Hole NEDD006 - 407.7m: chalcopyrite-pyrite rich quartz-carbonate-magnetite-hematite veins intersecting weakly propylitically altered intermediate volcanic rocks, returning elevated copper (1310 ppm) with gold (0.431 g/t) and minor molybdenum, silver and zinc.Hole NEDD006 - 417.25m: chalcopyrite-pyrite bearing quartz-carbonate-chlorite-hematite vein and dessiminated chalcopyrite-pyrite within weakly propylitically altered intermediate volcanic rocks with elevated copper (234 ppm) with minior gold, molybdenum, silver and zinc.Hole NEDD007 - 384.45m: chalcopyrite-pyrite-bornite rich quartz-carbonate-specular hematite veining intersecting weakly propylitically altered intermediate volcanic rocks, returning elevated copper (3400 ppm) and gold (0.341 g/t), with minior molybdenum, silver and zinc.Hole NEDD007 - 519.5m: chalcopyrite-pyrite rich quartz-carbonate-chlorite veins intersecting strongly propylitic-sodic altered hydrothermal breccia, returning elevated copper (13700 ppm) with gold (0.475 g/t) and molybdenum (31.8 ppm) with minor silver, lead and zinc.Hole NEDD007 - 557.4m: hydrothermal breccia with a quartz-carbonate+chlorite cement hosting disseminated chalcopyrite mineralization, returning elevated copper (812 ppm) and gold (0.28 g/t) with minior molybdenum and silver.ABOUT THE NJNB PROJECT PORTFOLIOThe Macquarie Arc is a hotspot for recent corporate activity with over A$16-billion of M&A for producing porphyry assets and over A$385 million of exploration earn-in/joint ventures 6. The district has seen considerable exploration success, including two greater than 10Moz gold equivalent discoveries/resource expansions 7 and an emerging gold discovery by Waratah Resources at the Spur project 8 and LinQ Minerals at the southern zone of the Gilmore project 9.Despite regional magnetics effectively mapping the Macquarie Arc volcanic belts, due to the post mineral cover, there has been very limited prior drilling of the extensions of both the Junee-Narromine and Molong volcanic belts relative to the southern more outcropping sections which hosts a number of world-class deposits and mines (e.g. Cadia, Cowal and Northparkes).Kincora's portfolio and the wider NJNB offers new district-scale discovery potential with spatial and temporal settings, coupled with magnetics, gravity and new Ambient Noise Tomography (ANT) surveys, supportive of large-scale targets analogous to porphyry deposits located in the southern section of the Arc.AngloGold Ashanti has secured Earn-in and Joint Venture Agreements with both Kincora and Inflection Resources (AUCU.CSE) ("Inflection", market capitalisation C$31.3 million) within the NJNB with over A$20 million investment to date 10. In 2Q'2025, AngloGold Ashanti moved to Phase II of its earn-in agreement with Inflection designating a total of four projects to continue earning into (including two projects adjacent to Kincora's Nyngan project) 11 and signed a major amendment with Kincora to include a second joint venture supporting a continuous strike greater than a 100kms and five projects.The most recent notable example of a new globally significant emerging porphyry district is the Vicuña district, which is also an extension of a renowned world-class porphyry belt. Vicuña is an extension of the central Andean belts in Argentina on the border of Chile and situated at over 4000m altitude.Within this district NGEx Resources Inc in 2009 held three early-stage exploration projects and at the time had a market capitalisation of approximately C$40 million 12. These same projects are all still at a pre-development phase but have yielded in four large-scale discoveries valued at over A$11 billion 13.Kincora was an early mover into the NJNB and has opportunistically pegged strategically important ground directly from the State resulting in a district scale portfolio of the interpreted most prospective and shallow to moderate covered part of the northwards extension of the Macquarie Arc under post mineral cover. This portfolio now covers a strike twice the length of the Vicuña district and is included in earn-in and agreements with AngloGold Ashanti.ABOUT KINCORAKincora Copper Limited (ASX: KCC) (TSXV: KCC) is an emerging Australia-focused copper-gold explorer with a hybrid prospect generator strategy. The Company is now successfully proving up the prospectivity of its extensive project portfolio, which includes multiple district-scale landholdings and scalable drill ready targets. These assets are located in Australia's Macquarie Arc and Mongolia's Southern Gobi, two of the globe's leading porphyry belts, and the historical Condobolin mining field within the Cobar Basin in NSW.Kincora is using an asset level partner model to develop and implement exploration strategies for its wholly-owned large-scale exploration stage porphyry projects. The Company has already unlocked over $100 million of potential partner funding for multiple earlier stage and/or non-core porphyry projects 13. These initial deals have supported over 16,000 metres of drilling and over A$7m of partner funded exploration since late 2024 until September 30, 2025, with management fees and exploration ramping up 14.Partner discussions are ongoing for its remaining 100% owned flagship projects that are all situated within existing porphyry camps containing over 20-million-ounce gold equivalent resource inventory.Kincora's ambition is to be the operator for exploration budgets of over $10 million per annum for the porphyry portfolio providing sufficient project management fees for the Company to be self-funding (covering corporate costs and maintenance of remaining wholly owned projects) and have partnerships with a diversified portfolio of industry leading producers/explorers. This is in addition to the various other existing partnerships where Kincora is not the operator or receiving a management fee income stream.The Company has assembled an industry leading technical team who have made multiple world-class copper and gold discoveries, who have "skin in the game" equity ownership, and, backed by a consolidated and sophisticated shareholder register. In Septmber 2025, Kincora closed an oversubscribed C$4 million non-brokered private placement of units led by leading North American investors, including Rick Rule and Jeff Phillips, and their investor networks.The share units have a 12-month hold period and there is an accelerator on the warrants - both at the lead investors requests. This raising is concurrent with a corporate restructuring and share capital roll back with only 43-million shares outstanding and over 60% of the register held by reporting insiders and/or in 12-month hold stock.The roll back and placement terms provides Kincora the corporate structure to leverage the deals, partner funding and project results already in place and to unlock significant existing value. This is starting to be realized.The new capital provides the ability to accelerate more drilling, do more asset level deals, earn more management fees, and, ultimately, supporting the ambition of more (big) new discoveries. These multiple avenues all provide further material value catalysts for shareholders.The financing also supports Kincora pursuing a hybrid project generator model and undertaking drilling at our 100% owned Condobolin project. The Condobolin project hosts a historical mining field located within the Cobar Basin and within trucking distance to an existing mill seeking third party ore. The Cobar Basin has recently seen a number of significant new discoveries (eg Federation, Achilles, Mallee Bull, Southern Nights and Wagga Tank) and significant corporate activity (eg Harmony's A$1.6 billion takeover of MAC, Kingston Resources receiving A$50 million cash for the first tranche of its divestment of its Misima project etc). The project and regional profiles' support the Condobolin project being an asset that a junior explorer such as Kincora can add significant value too.By having a significant portfolio of partner funded large porphyry projects, and a very focused program on a 100% owned project, the Company is seeking to position Kincora as a leading institutional grade explorer in the public Australian and Canadian markets, and the leading project generator on the ASX.To learn more, please visit: www.kincoracopper.comThis announcement has been authorised for release by the Board of Kincora Copper Limited (ARBN 645 457 763)For further information please contact:Sam Spring, President and Chief Executive Officersam.spring@kincoracopper.com or +61431 329 345Laurie Thomas, Strategic Advisorlaurie.thomas@kincoracopper.com or +1306 341 3826Media contactJulia Maguire, Managing Director, The Capital Networkjulia@thecapitalnetwork.com.au or +61 2 7257 7338Executive office400 - 837 West Hastings StreetVancouver, BC V6C 3N6, CanadaTel: 1.604.283.1722Subsidiary office AustraliaC/- JM Corporate ServicesLevel 6, 350 Collins StreetMelbourne, VIC, Australia 3000Qualified PersonThe scientific and technical information in this announcement was prepared in accordance with the standards of the Canadian Institute of Mining, Metallurgy and Petroleum and National Instrument 43-101 - Standards of Disclosure for Mineral Projects ("NI 43-101") and was reviewed, verified and compiled by Kincora's staff under the supervision of Peter Leaman (M.Sc. Mineral Exploration, FAusIMM), Senior Vice-President of Exploration of Kincora, and John Holliday (BSc Hons, BEc, member of the Australian Institute of Geoscientists), Non-Executive Director and Chairman of Kincora's Technical Committee, who are Qualified Persons for the purpose of NI 43-101.JORC Competent Person StatementInformation in this announcement that relates to Exploration Results, Mineral Resources or Ore Reserves are those that have been previously reported (with the original release referred to in this announcement), in the case of Mineral Resources or Ore Reserves the material assumptions and technical parameters underpinning the estimates have not materially changed, and have been reviewed and approved by John Holliday and Peter Leaman, who are Competent Persons under the definition established by JORC and has sufficient experience which is relevant to the style of mineralisation and type of deposit under consideration and to the activity being undertaking to qualify as a Competent Person as defined in the 2012 Edition of the 'Australasian Code for Reporting of Exploration Results, Mineral Resources and Ore Reserves'. John Holliday and Peter Leaman consents to the inclusion in this report of the matters based on his information in the form and context in which it appears. The review and verification process for the information disclosed herein for the Nyngan Projects have included the receipt of all material exploration data, results and sampling procedures of previous operators and review of such information by Kincora's geological staff using standard verification procedures.Forward-Looking StatementsCertain information regarding Kincora contained herein may constitute forward-looking statements within the meaning of applicable securities laws. Forward-looking statements may include estimates, plans, expectations, opinions, forecasts, projections, guidance or other statements that are not statements of fact. Although Kincora believes that the expectations reflected in such forward-looking statements are reasonable, it can give no assurance that such expectations will prove to have been correct. Kincora cautions that actual performance will be affected by a number of factors, most of which are beyond its control, and that future events and results may vary substantially from what Kincora currently foresees. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration results, continued availability of capital and financing and general economic, market or business conditions. The forward-looking statements are expressly qualified in their entirety by this cautionary statement. The information contained herein is stated as of the current date and is subject to change after that date. Kincora does not assume the obligation to revise or update these forward-looking statements, except as may be required under applicable securities laws.Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) or the Australian Securities Exchange accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/283322 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

EssexBio Bolsters Commitment to Ophthalmology Innovation at APAO 2026 in Hong Kong

HONG KONG, Feb 10, 2026 - (ACN Newswire via SeaPRwire.com) – Essex Bio-Technology Limited (“EssexBio” or the “Company”; Stock Code: 1061.HK) today announces its successful participation in the 41st Asia-Pacific Academy of Ophthalmology Congress (APAO 2026), held from 5 to 8 February 2026 at the Hong Kong Convention and Exhibition Centre.APAO 2026 drew an impressive crowd of approximately 11,000 ophthalmologist and industry professionals from the Asia-Pacific region.  APAO 2026 provided an excellence platform for Essexbio to showcase our key ophthalmology products and research pipeline. Our team engaged with attendees at our booth, highlighting the Company’s growing presence and commitment to advancing eye care innovations in the Asia-Pacific region.Notably, Essexbio was selected for an oral presentation for its poster, “Anatomical and Patient-Reported Outcomes of Bevacizumab Versus Ranibizumab in Wet Age-Related Macular Degeneration: The AURA-1 Study”. The presentation underscored the Company’s ongoing clinical advancements in anti-VEGF therapies for wet age-related macular degeneration (wAMD), building on its Phase III data for its bevacizumab candidate (EB12-20145P).Additionally, EssexBio was the sole sponsor of the APAO Young Ophthalmologists (YO) event, demonstrating its dedication to nurturing future leaders in ophthalmology. Through the EssexBio Academy, we support professional development and knowledge sharing amongst emerging talents in the field.Please download more high-resolution photos via link:https://drive.google.com/drive/folders/1kWQayVTyEbXt_824u5xbACBkKECr57Sb'usp=sharingAbout EssexBio (1061.HK)EssexBio is a bio-pharmaceutical company that develops, manufactures, and commercialises genetically engineered therapeutic b-bFGF, with six commercialised biologics currently marketed in China. Additionally, the Company has a diverse portfolio of commercialised preservative-free unit-dose eye drops, Shilishun(R)) (Iodized Lecithin Capsules) and others, which are principally prescribed for wound healing and diseases in Ophthalmology and Dermatology. These products are marketed and sold through approximately 14,100 hospitals, supported by the Company’s 46 regional offices in China. Leveraging its in-house R&D platform in growth factor and antibody technology, EssexBio maintains a robust pipeline of projects in various clinical stages, covering a wide range of fields and indications. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

CTF Life+ Announces Winners of Financial Empowerment Case Competition, Innovative Platform Advances Intergenerational Inclusion

HONG KONG, Feb 10, 2026 - (ACN Newswire via SeaPRwire.com) –  CTF Life has successfully concluded its inaugural “Financial Empowerment · Life Companion” case competition, marking a significant milestone for its flagship annual youth programme, CTF Life+. The competition adopted an innovative “Competition x Internship” dual-track format, connecting tertiary students to foster intergenerational inclusion while promoting financial literacy and sustainable development in Hong Kong. The initiative received an enthusiastic response from academic, financial, and social innovation sectors, underscoring CTF Life’s steadfast commitment to translating environmental, social, and governance (ESG) principles into concrete action.Eleonore Chow, Chief Executive of Agency at CTF Life, said, “Our financial empowerment case competition puts the social element of ESG into action. By harnessing resources within the Chow Tai Fook Group ecosystem, we guided students to integrate business thinking with social innovation to create shared value for Hong Kong. This demonstrates that the insurance industry is evolving from its traditional product provider role to a partner that actively promotes social protection, while also creating value beyond dreams for the younger generation.”Established last year, CTF Life+ aims to nurture young people with innovative thinking and a strong sense of social responsibility, while deepening their understanding of the insurance industry, ESG principles, and social innovation. Leveraging the Chow Tai Fook Group ecosystem, participants assumed the role of “Life Planners”, designing impactful financial education solutions for communities with limited financial knowledge, including young people, the elderly, and new arrivals to Hong Kong.Winners of the case competition InstitutionSolutionSummary of MeritsChampionThe University of Hong Kong & The Chinese University of Hong KongChairs for the elderlyThe project empowers both the elderly and young volunteers through a sustainable and feasible concept.Firstrunner-upCity University of Hong Kong,HKU Space & Hong Kong Baptist UniversityThe Gold Athlete ProgrammeInnovative approach and compelling presentation with real-life examples demonstrating a deep understanding of the target audience.Second runner-upThe Hong Kong University of Science and Technology & City University of Hong KongSecond Life PassportThe proposal makes extensive use of group resources and demonstrates careful consideration of execution details.The competition attracted more than 150 students from tertiary institutions across Hong Kong. Participants formed teams of two to six, either from the same institution or across different institutions, while individual applicants were grouped by the organiser to encourage diverse collaboration. The teams proposed innovative solutions spanning digital wealth management tools, community education programmes, and intergenerational financial coaching platforms. In addition to a HK$50,000 cash prize, the champion team will also be eligible to receive seed funding from CTF Life+ to transform their innovative concepts into viable projects. The judging panel featured representatives from various industry organisations, ensuring the competition’s professionalism and credibility.The competition also placed strong emphasis on practicality and personal development through a “mentorship” model, pairing each team with a CTF Life mentor to foster intergenerational dialogue and knowledge transfer. As “Young Changemakers”, students immersed themselves in the community to better understand the financial management challenges faced by disadvantaged groups and propose practical, innovative solutions. This mutually enriching model not only provided students with real-life workplace experience but also offered the organisation meaningful inspirations from the younger generation.The grand final of the “CTF Life+” Case Competition was successfully held on 7 February, with the top 10 finalist teams delivering outstanding performances and presenting innovative proposals on financial empowerment that balanced creativity with practical feasibility.About CTF LifeChow Tai Fook Life Insurance Company Limited (“CTF Life”) is proud of its rich, 40-year legacy in Hong Kong. CTF Life is a wholly-owned subsidiary of CTF Services Limited (“CTFS”) (Hong Kong Stock Code: 659) and one of the most well-established life insurance companies in Hong Kong. As a member of Chow Tai Fook Enterprises Limited, CTF Life consistently strengthens its collaboration with the Chow Tai Fook Group ecosystem to support customers and their loved ones in navigating life’s journey with personalised planning solutions, lifelong protection and diverse lifestyle experiences. By leveraging the Group’s robust financial strength and strategic investments across the globe, CTF Life aspires to become a leading insurance company in Asia while continuously creating value beyond insurance.Chow Tai Fook Life Insurance Company Limited (Incorporated in Bermuda with limited liability) Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Mint Signed MoU with Robotics Leader Rice Robotics to Pioneer Physical AI Solutions Across Asia

HONG KONG, Feb 10, 2026 - (ACN Newswire via SeaPRwire.com) –  Mint Incorporation Limited (“Mint” or the “Group”, NASDAQ: MIMI), a Hong Kong-based company with a new strategic focus on artificial intelligence (AI) and robotics, and an established business interior design and fit-out works provider, today announced that its wholly-owned subsidiary, Aspiration X Limited (“Aspiration X”), has signed a non-binding Memorandum of Understanding (“MOU”) to explore the formation of a strategic joint venture with a renowned delivery robotics company, Rice Robotics Holdings Limited (“Rice Robotics”). Under the MOU, both parties intend to establish a joint venture with an initial investment of approximately HK$10,000,000 to be funded by Mint, subject to the negotiation and execution of definitive agreements. The proposed collaboration centers on a shared goal of developing localized robotic technologies and expanding related research and development (“R&D”) capabilities in Hong Kong.At its core, the proposed joint venture aims to accelerate the development and deployment of intelligent robotic solutions. Mint brings its established footprint in Southeast Asia—including smart office solutions in Singapore and security robot deployments in Thailand and Malaysia—while Rice Robotics contributes its expertise in delivery robots and a robust presence in Japan, serving prestigious clients. The parties intend to leverage their respective strengths in terms of R&D, marketing, and branding to achieve expansive market coverage.   Commenting on the strategic initiative, Mr. Damian Chan, Chairman of the Board and Chief Executive Officer of Mint stated: “This partnership provides a compelling response to the question, ‘Why not Hong Kong'’ While the city is renowned for fintech and finance, we believe it has the talent and vision to be a leader in physical AI and robotics innovation. Many local firms act mainly as sales channels, but together with Rice Robotics, we are building core proprietary technology here. We were impressed by Rice Robotics’ proven delivery robotics platform and its network of high-profile clients in Japan. This partnership significantly diversifies and strengthens our robotics portfolio, allowing us to move beyond B2B into the promising B2C space—developing robots for companionship, education, and daily life, powered by our robust AI.”Mr. Victor Lee, Founder of Rice Robotics, added: “Mint’s rapid expansion in AI and robotics across Southeast Asia makes it an ideal partner. Its dedicated commercial teams and AI platform will dramatically accelerate our joint R&D and market expansion. We share a bold vision to build the most anticipated robotics company in Hong Kong and drive meaningful diversification in the region’s tech ecosystem. This joint venture will serve as a strategic accelerator for both companies.”The collaboration is strategically timed to capitalize on the transformative shift towards "Physical AI"—systems capable of reasoning, planning, and acting autonomously in the real world. By combining Rice Robotics’ proven robotics hardware and market expertise with Mint’s advanced AI platform, the joint venture will occupy a unique position at the forefront of this revolution. Both partners are committed to developing smarter, more intuitive robotic solutions that address real-world challenges, enhance everyday life, and set the stage for the next generation of autonomous technology.The MOU is non-binding and subject to the execution of definitive agreements and satisfaction of customary conditions.About Mint Incorporation LimitedMint Incorporation Limited (NASDAQ: MIMI), a Hong-Kong based enterprise listed on NASDAQ, specializes in artificial intelligence (AI), robotics, and interior design. Through its subsidiary Aspiration X, the company delivers intelligent robotics and facility management solutions to enterprises, real estate, shopping centers, government agencies, and more. Mint also operates Matter International Limited, providing professional interior design and renovation services. With a focus on innovation and practical applications, Mint is committed to enhancing efficiency, safety, and quality of life across industries.Rice Robotics Holdings LimitedRice Robotics Holdings Limited is a renowned leader in autonomous delivery robot solutions, with a strong market presence across Asia. The company specializes in the design, development, and deployment of intelligent robotic systems for logistics and service industries. Its core technology platforms serve high-profile clients in Japan, demonstrating proven reliability in complex operational environments.  With a focus on innovation and real-world application, Rice Robotics is committed to transforming last-mile delivery and service automation, enhancing operational efficiency and redefining customer experiences.Forward-Looking StatementsCertain statements in this release are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results disclosed in the Company's filings with the SEC. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Spritzer EcoPark Gallops into the Year of the Horse with a Tradition-Inspired Chinese New Year Celebration

Festive decorations transform the park into a mesmerising cultural experience, celebrating prosperity, renewal and togethernessTAIPING, Malaysia, Feb 10, 2026 - (ACN Newswire via SeaPRwire.com) - This Chinese New Year, Spritzer EcoPark invites all Malaysians to join in on the energy and excitement in welcoming the Year of the Fire Horse! Set against the vibrant and verdant backdrop of where tradition meets nature in Malaysia’s rainiest town of Taiping, Spritzer EcoPark continues their annual tradition to inspire and promote togetherness, reflection, and fresh beginnings.From this February to early March 2026, Spritzer EcoPark comes alive as a Chinese New Year cultural village, offering visitors an immersive walk-through experience designed to reflect prosperity, good fortune and new beginnings. In the same spirit, admission is free to ensure the Spritzer EcoPark remains an accessible destination for families and visitors of all ages.In Chinese culture, the Horse symbolises vitality, perseverance, freedom, and forward momentum, which are qualities closely associated with breakthroughs and stepping boldly into new opportunities. As the zodiac cycle moves from the reflective, introspective energy of the Year of the Snake, the dynamic Year of the Horse is expected to usher in a shift towards confident action.Figure 1: One of the many horse-themed Chinese New Year outdoor decorations at Spritzer EcoPark.Drawing inspiration from this symbolism, Spritzer EcoPark’s festive transformation aims to capture the essence of the New Year and zodiac, encouraging visitors to step into the year with optimism, courage, and a renewed spirit. Thoughtfully curated decorations weave traditional Chinese New Year elements into the park’s lush natural surroundings. Festive arches, pavilion-inspired structures, glowing red lanterns, cherry blossoms, auspicious symbols, Horse and zodiac motifs/decor, and interactive display zones turn the park into a charming, photo-worthy landscape, perfect for capturing meaningful memories with family and friends while enjoying the festive atmosphere.As one of Taiping’s must-visit destinations for locals and tourists alike, Spritzer EcoPark offers a range of engaging activities suitable for visitors of all ages. Families can enjoy in DIY & Crafting sessions, try their hand at Mini Golf with LED Golf Balls and take part in a friendly race on the Paddle Carts amidst the fresh Taiping air, all available at affordable prices. For visitors looking to slow down amidst the festivities, STG Taiping café offers a cozy and relaxing spot to unwind and recharge with refreshing drinks and snacks. Those who do not want to go home empty-handed can also stop by the Spritzer Water Shop to stock up on Spritzer beverages for festive gatherings or explore the exclusive souvenirs and seasonal promotions at the Souvenir Shop.Figure 2 and 3: Spritzer EcoPark's decorations are thoughtfully curated to weave traditional Chinese New Year elements into the park’s lush natural surroundings.More than a seasonal attraction, Spritzer EcoPark reflects the brand’s commitment to wellness, creativity, sustainability and meaningful shared experiences. Surrounded by nature and guided by Spritzer’s values, the EcoPark provides a relaxing space for visitors to slow down, reconnect with loved ones and celebrate the simple joys of the season.Winnie Chin, Head of Public Relations at Spritzer said, “Each year, Spritzer strives to create fresh and memorable experiences for our visitors. The Year of the Horse represents progress and vitality, and we want this celebration to reflect those qualities through an immersive environment that brings families together in these natural surroundings. Our goal is to offer a space where people can relax, reconnect, stay hydrated and begin the new year feeling refreshed and inspired.”Spritzer EcoPark extends its warmest wishes for a Happy Chinese New Year. May the Year of the Fire Horse bring prosperity, wellness, and joy for all.The park is open daily from 10:00 AM to 9:30 PM and is located at Lot 898, Jalan Reservoir, Off Jalan Air Kuning, 34000 Taiping, Perak.For the latest news and updates, follow Spritzer EcoPark on Facebook and Instagram. For more high-resolution photos, please download them here.About SpritzerEstablished in 1989, Spritzer is a leading Malaysian bottled water brand, sourcing natural mineral water from a protected 430-acre rainforest in Taiping. Naturally filtered through underground rock layers for over 15 years, our water is enriched with essential minerals like Silica, known to support skin, bones, hair, and nails.Combining smart manufacturing with sustainable practices, Spritzer ensures every bottle meets the highest quality and safety standards. Our packaging is 100% recyclable and made from recycled materials, reflecting our commitment to environmental stewardship and a circular economy.Tested annually by SIRIM to be free from microplastics, Spritzer offers consumers trusted, natural hydration. Our diverse product range includes Natural Mineral Water, Original and Flavoured Sparkling Water, Distilled Water, and Fruit-Flavoured Beverages—crafted to suit every lifestyle and occasion.With a clear vision to become a fully circular brand by 2030, Spritzer leads the industry in innovation, quality, and sustainability.Spritzer — where nature, innovation, and sustainability come together in every bottle.For more information, visit www.spritzer.com.myFor media inquiries please contact:Imelia KyraAssociate Consultant, Narro CommunicationsE: imelia@narrocomms.comWinnie ChinHead of Public Relations, Spritzer BhdE: winniecgl@spritzer.com.my Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

CITIC Telecom CPC Wins Two Awards, Celebrating ‘Innovation Never Stops’ for 25 Years, recognizing Cybersecurity & Innovation Excellence

HONG KONG, Feb 9, 2026 - (ACN Newswire via SeaPRwire.com) – CITIC Telecom International CPC Limited (“CITIC Telecom CPC”), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883) is pleased to announce a triumph in winning two prestigious awards as 2026 unfolds, recognizing its cybersecurity and continuous innovation capabilities. CITIC Telecom CPC’s AI-driven Security Operations Centre (AI SOC) is honored “Best AI SOC Service Provider” in “IT PRO Corporate Choice Award 2025” from the well-known IT media . In addition, two security experts of CITIC Telecom CPC have won two accolades in “Internet and Cloud Services” sector of “Cyber Security Professional Awards 2025” organized by the Hong Kong Police Force (Cyber Security and Technology Crime Bureau, CSTCB).Mr. Brook Wong, Chief Executive Officer of CITIC Telecom CPC, said, “2026 marks the 25th anniversary of CITIC Telecom CPC. Our tagline “Innovation Never Stops for 25 Years. Empowering a Smarter Future” embodies 25 years of continuous innovation, driving the creation of a more secure and highly efficient digital future. We strive to enhance our solutions to address the evolving needs of our customers and drive innovation in an ever-changing landscape. We empower enterprises to leverage innovative security solutions to elevate operational efficiency, supporting their “Going Global” and “Coming to China” efforts with tailored strategies, and being the trusted DICT service partner of multinational corporations and enterprise customers. We are honored to receive the “Best AI SOC Service Provider” Award and the “Cyber Security Professional Awards 2025”, a testament to our enduring commitment to cybersecurity innovation and the technical expertise of our talented professional team, driving groundbreaking solutions development through technological innovation.”CITIC Telecom CPC proudly presents the following accolades:“IT PRO Corporate Choice Award 2025”- “Best AI SOC Service Provider”“Cyber Security Professional Awards 2025” - 2 Accolades in “Internet and Cloud Services” sectorCITIC Telecom CPC clinches “Best AI SOC Service Provider” of“IT PRO Corporate Choice Award 2025”Garners IT PRO Corporate Choice Award 2025CITIC Telecom CPC’s AI SOC has been bestowed with the "Best AI SOC Service Provider" of the ‘IT PRO Corporate Choice Award 2025” for the first time. This award honors CITIC Telecom CPC's customer-focused innovative security solutions that address enterprises’ evolving needs in an increasingly complex cyber threats environment. It also serves as a testament to CITIC Telecom CPC's unwavering dedication to delivering top-tier AI-driven security services, which are widely valued by enterprise customers across different industries. CITIC Telecom CPC’s cutting-edge SOC technologies have been highly acclaimed in the industry. The company was honored one of the top three most trusted Security Operations Centers (SOCs) in Hong Kong according to the “IT PRO Corporate SOC Survey[1]” conducted by in April 2025, recognizing its technical expertise and market leadership in security operations.Leveraging groundbreaking and robust AI technologies, AI SOC significantly enhances the overall efficiency of SOC. As the core of AI SOC, SIEM-MiiND is a self-built and managed intelligent security information and event management (SIEM) platform. It utilizes big data and intelligent technologies to boost the detection capabilities of AI SOC, optimize rule sets, improve response capabilities, provide AI-powered chatbot and user-friendly security dashboard, enabling cost-effective and robust security protection for enterprises, and reshaping the future cybersecurity model. Two Cybersecurity Experts Win Two Accolades in Cyber Security Professional Awards 2025Organized by the Hong Kong Police Force (CSTCB), Cyber Security Professional Awards 2025 aims to recognize outstanding industry talent, foster innovation, and strengthen public-private collaboration to jointly enhance Hong Kong’s cybersecurity. Two security experts of CITIC Telecom CPC received two accolades in “Cyber Security Professional Awards 2025” Thomas KT Wong, Director of Security Services Delivery & Operation, and Sung Liu, Security Specialist of CITIC Telecom CPC received Silver and Merit Awards respectively in the “Internet and Cloud Services” sector of “Cyber Security Professional Awards 2025”. Both of them have over 10 years of network security experience. Thomas KT Wong is instrumental in managing the SOCs of CITIC Telecom CPC. He leads a team of security experts to provide 24/7 security monitoring and incident response services, thereby safeguarding enterprise cybersecurity. Sung Liu is responsible for core technologies support, providing comprehensive and practical security solutions to address enterprise pain points. The two awardees have extensive industry experience, profound knowledge and technical expertise, facilitating CITIC Telecom CPC in maintaining its competitive edges in the cybersecurity market and further reaffirming its professionalism and commitment to the cybersecurity sector.About CITIC Telecom CPCWe are CITIC Telecom International CPC Limited (“CITIC Telecom CPC”), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883), serving multinational enterprises the world over by addressing their specific ICT requirements with highly scalable tailored solutions built upon our flagship technology suites, comprising TrueCONNECT™ private network solutions, TrustCSI™ information security solutions, DataHOUSE™ cloud data center solutions, and SmartCLOUD™ cloud computing solutions.With the motto “Innovation Never Stops,” we leverage innovative technologies to boost technology empowerment (+AI). Embracing AI, AR, Big Data, IoT, and other cutting-edge emerging technologies we aim to unlock technical potential. By integrating deep learning and intelligent data analysis technologies, we transform these technologies into data empowerment (AI+) generative applications, reshaping the Intelligence Operation Journey of enterprises.With our Global-Local capabilities, we are committed to providing our customers with one-stop-shop ICT solutions with superior quality. Having a worldwide footprint across nearly 160 countries and regions, including Asia, Europe and America, Africa, the Middle East, and Central Asia, our global network resources connect nearly 170 points of presence (POPs), 60+ SD-WAN gateways, 20 Cloud service centers, 30+ data centers, and three dedicated 24x7 Security Operations Centers (SOCs). We are certified with a series of international certifications, including SD-WAN Ready, ISO 9001, 14001, 20000, 27001, and 27017, to ensure our services compliance with international standards and resources for enterprises.  We offer local professional services, superior delivery capabilities as well as exceptional customer experience and best practices through our global presence and extensive industry know-how, becoming a leading integrated intelligent ICT service provider to enterprise customers.For more information, please visit www.citictel-cpc.com.Media Contacts:Catherine YuenCITIC Telecom CPC(852) 2170 7536 Email: catherine.yuen@citictel-cpc.com[1] The survey was conducted online by IT PRO via email questionnaire to more than 12,000 mid to senior-level executives in local enterprises in April 2025. Source (Chinese only): https://itpromag.com/2025/05/16/it-pro-soc-result Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

playX Secures Industry-Leading Player Protection Through Landmark Insurance Partnership with Great American Insurance Group

KUALA LUMPUR, Feb 8, 2026 - (ACN Newswire via SeaPRwire.com) - playX today announced a milestone achievement in player protection, unveiling an industry-leading insurance policy secured through a strategic partnership with Great American Insurance Group (GAI), a trusted provider of gaming insurance solutions since 1995. The announcement was made during a special company event in Kuala Lumpur, highlighting playX's continued commitment to strengthening financial safeguards for players across its platform.Official Video: https://www.youtube.com/watch?v=EpvceD-HJyUWhat This Means for PlayersThe policy directly protects all playX players. If playX ever ceases operations, players can file claims directly with GAI to recover their funds — a first in online gaming history.Direct claim rights with Great American Insurance GroupPlatform insolvency protection for all player fundsBacked by GAI's 30-year track record in gaming insuranceGuinness-verified player protection in online gaming"This isn't just a title — it's a guarantee that our players' funds are protected by an independent, globally recognized insurer, not just our promises," said Mark Carter, CEO of playX.About playXPremier online gaming platform serving Southeast Asia, combining cutting-edge technology with industry-leading security.About Great American Insurance GroupCentury-old insurance provider; Fidelity & Crime division has led gaming insurance since 1995.Official ChannelsFacebook: https://www.facebook.com/playX.myInstagram: https://www.instagram.com/playx.my/Telegram: https://t.me/playXofficialYouTube: https://www.youtube.com/@playXOfficial8Media contactBrand: playXContact: Media teamEmail: marking@playxgaming.comWebsite: https://playx.my Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Mr Liu Xiaojun, on behalf of Fufeng Group, has fully completed the acquisition of Viva World Trade, Inc.

Hong Kong, Feb. 6, 2026 - (ACN Newswire via SeaPRwire.com) - Viva World Trade, Inc. ("VVWT" or the "Company"; OTCID:VVWT) is pleased to announce that Mr. Liu Xiaojun, on behalf of Fufeng Group ("Fufeng Group"; HK:00546), has successfully completed the full acquisition of the Company. This acquisition has fulfilled all necessary internal decision-making procedures and relevant regulatory requirements of OTC Markets. The transfer of equity and handover of control have been fully completed, and Mr. Liu Xiaojun, representing Fufeng Group, has formally become the sole controlling shareholder of the Company.Fufeng Group, established in Hong Kong in 2021, is a comprehensive multinational conglomerate focusing on four core business segments: international investment, cross-border trade, compliant crypto asset services, and global business agency. It is committed to providing integrated cross-border development solutions for enterprises through a dual-engine approach of "real industries + financial capital."Upholding the core operating philosophy of "Integrity, Professionalism, and Win-Win Cooperation," the Group has established multiple offices within China, building a diversified industrial ecosystem to precisely connect with premium global project resources and empower enterprises in achieving cross-border development and value enhancement. Notably, the Inner Mongolia Yellow Cattle Breeding Project (spanning 2,400 acres) has completed all preliminary preparations and is poised to enter large-scale operation, injecting robust growth momentum into the Group's real industry sector.Guided by the development logic of "industry empowering capital, capital driving industry," Fufeng Group has established its core strategic positioning: anchored in compliant operations, leveraging cross-border M&A and asset integration to facilitate the Nasdaq Main Board listing of its subsidiary Viva World Trade, Inc., thereby launching a new chapter in global capital operations.Future Planning and Strategic Deployment (Through Q1 2026)To accelerate the realization of the Group's overall strategic objectives, Fufeng Group has outlined clear directives for its affiliated entity Viva World Trade, Inc., planning to complete the following key strategic steps by the end of March 2026:1. Advance Crypto Asset Strategic Integration: By late February 2026, negotiate and execute a "triangular reverse merger transaction" with a leading crypto-native asset company. This aims to efficiently integrate innovative value from cutting-edge digital asset sectors, injecting fresh growth momentum into the Group.2. Introduce Professional Capital Services Partner: By late March 2026, establish deep cooperation with a professional investment institution possessing extensive market experience. This partnership will assist the company in global market expansion, enhance compliance operations to increase market visibility and capital allocation efficiency, and solidify the foundation of corporate value.3. Secure NASDAQ Listing Pathway: By the end of March 2026, the company plans to engage a professional advisory firm with expertise in U.S. stock market listings. A dedicated listing advancement team will be established to formally initiate preparations for a NASDAQ Main Board listing, laying a solid foundation for compliance filings and the transition to the main board.Viva World Trade, Inc. on OTC Markets: https://www.otcmarkets.com/stock/VVWT/profileForward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on management's current plans and expectations and are subject to various uncertainties and risks that could materially affect the company's current plans and expectations, as well as its future operating results and financial condition. For a more detailed list of risks and factors that could affect the Company's business prospects and cause actual results to differ materially from those described in forward-looking statements, please refer to the Company's reports and other filings with the U.S. Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.Please contact:GEMZ CORPhyxinvest@yeah.net  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

GIC Invests US$100M in Ascletis Pharma (1672. HK): Anchoring Long-Term Capital in China’s Core Innovative Drug Assets

HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – According to disclosure of interests filed with the Hong Kong Stock Exchange (HKEX), the Government of Singapore Investment Corporation (GIC) has acquired an initial stake in Ascletis Pharma (1672. HK). GIC purchased 64,128,000 shares at an average price of approximately HK$12.18 per share, representing a total investment of roughly HK$781 million (approx. US$100 million). This transaction marks the official entry of one of the world's leading sovereign funds into Ascletis Pharma's shareholder base, drawing market attention to the renewed positioning of global long-term capital in China's innovative pharmaceutical sector.As one of the most representative sovereign funds globally, GIC's investment decisions highly emphasize certainty and the ability to navigate economic cycles. Its continuous increase in holdings in a single target usually means that its mid-to-long-term value judgment on the relevant assets has become clear. Unlike tactical transactions by short-term funds, GIC focuses more on whether the industrial logic is sound, whether R&D realization has time visibility, and the potential returns over the next few years.From a portfolio allocation perspective, GIC's decision to invest in Ascletis Pharma also reflects, to a certain extent, its recognition of the company's BD capabilities and pipeline structure. Ascletis Pharma's strategic layout in the innovative drug field exhibits differentiated characteristics, with a clear R&D pace. Its pipeline structure highly matches the "long-term, verifiable innovation" standards preferred by sovereign funds.As of now, GIC holds 64,128,000 shares of Ascletis Pharma, accounting for approximately 6.42% of the company's issued share capital (calculated based on 1,068,214,530 issued shares).Overall, GIC's current investment is more a strategic continuation of its presence in the Hong Kong innovative drug sector, rather than a short-term speculative behavior. As long-term capital gradually returns to fundamental pricing, core targets with genuine BD capabilities are re-entering the allocation scope of international capital. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share

HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – According to the disclosure of interests information released by the Hong Kong Stock Exchange, on 5 February, GIC Private Limited made its first equity investment in Ascletis Pharma (01672) by acquiring 64,128,000shares at a price of HKD12.18per share, involving a total consideration of approximately HKD781.08million (equivalent to approximately USD100.01 million). Following the transaction, GIC's shareholding in Ascletis Pharma amounted to 64,128,000shares, representing a shareholding percentage of 6.42%, marking GIC's initial entry into the company's shareholder base. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

COSMOPlat Introduces Full-Stack AI to Hong Kong for Trillion-Dollar Industrial Digitalization

HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – Currently, digital transformation has become the core proposition of global industrial upgrading, and the manufacturing industry is also undergoing a disruptive transformation from being “experience-driven” to “data intelligence-driven”. In this process, the deep integration of artificial intelligence and industrial scenarios has become the key to resolving manufacturing complexity and unleashing productivity.  The introduction of the Action Plan for Integrating and Empowering Industrial Internet and Artificial Intelligence by MIIT further marks the upgrade of “AI + Manufacturing” from an optional pathway to a mandatory one, giving rise to a blue ocean of value worth tens of trillions.As a deep participant and leader in the digital and intelligent transformation of the manufacturing industry, COSMOPlat IoT Technology Co., Ltd. (“COSMOPlat”) has, based on its profound understanding of massive data and complex scenarios in the industrial field, built a full-stack AI technology system that includes training and inference platform, large models, intelligent agent development and application platforms. This has not only redefined the implementation path of industrial digitalization and intelligentization, but also continuously strengthened its technical barriers in industrial practice, building a solid and difficult-to-replicate moat, and is expected to benefit deeply from the dividends of industrial digital and intelligent transformation and development. On January 30, COSMOPlat submitted a listing application to the HKEX, embarking on a new chapter of value realization.AI Restructuring Industrial Digitalization: Full-stack Architecture and Flywheel Effect Build Core BarriersIn traditional perception, the industrial internet is a platform for data connection and circulation, and its technical boundaries remain more at the levels of equipment access, data collection, and process visualization. However, through its original “space-air-ground integrated” full-stack AI technology system, COSMOPlat has deeply embedded “AI+” into its technology architecture, achieving an intelligent closed-loop across the entire chain from perception and decision-making to execution, transforming data into intelligent decision-making capabilities, completely overturning the technology logic of the traditional industrial internet, and building an inimitable technology moat.At the “space” level, COSMOPlat utilizes “COSMOMind”, the first domestic vertical large model based on an industrial internet platform, as its decision-making hub. “COSMOMind” deeply integrates Haier Group's over 40 years of manufacturing knowledge, as well as expert models and high-quality multimodal datasets accumulated on the COSMOMind Industrial Big Data. It possesses significant advantages in industrial scenario analysis, knowledge Q&A, and logical reasoning, with a retrieval accuracy rate of up to 93% in industrial knowledge fusion and retrieval. Through the "one industry, one model" strategy, COSMOPlat has developed industry-specific large models for enterprises in home appliances, energy and chemicals, energy and carbon industries, providing intelligent decision-making support for major industrial scenarios including research and development design, production manufacturing, operation services and dual-carbon management.Industry intelligent agents and industrial software serve as the “air link”, transforming the decision-making instructions of large models into more flexible human-machine interaction methods and more efficient execution capabilities. As of the Latest Practicable Date, COSMOPlat has developed 57 industrial intelligent agents covering over 40 core scenarios across 3 major industries, which can handle key industrial functions such as process optimization, equipment management, and smart energy and carbon, helping customers achieve intelligent control of industrial processes, shorten process parameter adjustment cycles, improve equipment operation and maintenance efficiency, and reduce production energy consumption and energy costs.At the “ground” level, intelligent terminals and automation equipment, acting as the executing limbs, transform AI capabilities into actual production actions and integrate them into the entire manufacturing process, achieving efficient synergy among data, equipment and scenarios, driving industrial AI from isolated intelligent applications to domain-wide intelligence, creating value-added throughout the entire process for customers across various industries, and maximizing the release of data value.Relying on the “space-air-ground integrated” full-stack AI technology system, COSMOPlat has achieved full-link intelligence across “perception-analysis-decision-execution-feedback”, forming a unique flywheel effect of “data accumulation—model refinement—intelligent agent deployment—data reinforcement”, achieving self-reinforcement and a virtuous cycle where “more data is generated through use, models become more precise through use, and intelligent agent scenarios become broader through use”, enabling COSMOPlat's AI capabilities to continuously evolve in practice and building a solid technology barrier.Practical Evidence: AI Empowerment from Concept to Significant Scenario Implementation ResultsThe value of technology must ultimately be tested by the market. COSMOPlat has demonstrated through numerous benchmark cases that its AI empowerment has moved beyond the “proof of concept” stage and is capable of delivering tangible economic benefits to enterprises.In the petrochemical industry, COSMOPlat has developed the world's first petrochemical large model covering the entire industry chain, entire ecosystem chain, and entire value chain, which has been implemented in a large-scale petrochemical enterprise. Based on the model, the Company has developed 38 intelligent agents, such as the dynamometer intelligent assistant and the aldehyde separation tower process optimization agent, covering scenarios such as oilfield extraction, oil and gas refining and chemical processing, and production safety, with an average efficiency increase of 20%. Taking the dynamometer intelligent assistant as an example, based on the professional capabilities of whole-network search and the COSMOMind, this intelligent agent can “read and understand” dynamometer data of industrial equipment such as deep well pumps, accurately identify equipment failures and provide disposal suggestions, improving the efficiency of oil well equipment failure diagnosis and disposal by more than 50%; the aldehyde separation tower process optimization assistant integrates historical data and expert knowledge, enabling dynamic identification and adjustment suggestions for key parameters, providing decision-making assistance for operators, and significantly enhancing quality control precision and the product first-time conversion rate; the intelligent oil blending assistant quickly generates optimal blending schemes through interpolation algorithms and non-linear programming models, balancing product performance with green production requirements, fully validating the practical value of AI in the heavy chemical industry.In core manufacturing scenarios, COSMOPlat integrates AI technology throughout the entire chain of R&D, production, operation and maintenance. On the R&D side, taking a home appliance interconnected factory selected as a world “lighthouse factory” as a typical example, an AIGC virtual design assistant was introduced. Based on massive user preference data and an expert design asset library, it generated core solutions for three-drum washing machines. By simulating inner drum operation scenarios in advance to construct a dynamic balance optimization model, it solved the industry pain point of “collisions and interference” during multi-drum operation at the source; on the production side, the injection molding industrial intelligent agent, through deep learning of injection molding professional knowledge, equipment operation data, and process data, etc., precipitated the debugging methods that previously existed only in the minds of process technicians into various intelligent algorithms, ultimately forming professional injection molding knowledge Q&A and automated process parameter recommendation capabilities, building the most powerful “industrial brain” in the field of injection molding.In the energy sector, COSMOPlat’s energy-carbon model (COSMOMind for energy-carbon) is the first energy-carbon model originating from sustainable lighthouse factory practices. Based on this model, COSMOPlat offers enterprises and industrial park users an Energy-Carbon Management Platform and end-to-end smart-energy solutions, helping customers lower energy cost, improve utilization and advance green manufacturing. These cross-industry and multi-scenario success stories strongly demonstrate the practical effectiveness and replicability of COSMOPlat’s AI solutions.From an industrial cycle perspective, as the manufacturing system grows increasingly complex and cost and efficiency constraints intensify, enterprises' demand for end-to-end digital and intelligent transformation will continue to rise, ensuring long-term certainty in industry development.COSMOPlat has pioneered the “space-air-ground integrated” technology system centered on large industrial models, with intelligent agents deeply embedded in production processes. This delivers a closed loop of perception, decision-making, and execution. Through multi-industry and multi-scenario validation, it demonstrates that AI possesses the capability to continuously generate industrial value. As application scenarios continue to expand, intelligent agents scale up, and the data flywheel effect intensifies, COSMOPlat is poised to translate its technological leadership into heightened platform stickiness and greater value per customer. Riding the wave of digital transformation, it is unlocking greater potential for value growth. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Distinct Healthcare Successfully Listed on HKEX, Bolstered by Premium Customer Base and All-Star Cornerstone Investors

HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – On February 6, Distinct Healthcare Holdings Limited ("Distinct Healthcare" or the "Company", Stock Code: 2677.HK), a leading player in China's mid-to-high-end consumer healthcare services market, was successfully listed on the main board of the Hong Kong Stock Exchange, emerging as a high-quality and rare private healthcare gem in the Hong Kong stock market. This marks the beginning of a new chapter in the Company's scaled and high-quality development.On its debut, Distinct Healthcare delivered a standout debut, opening sharply higher at HK$81 per share (a 35.23% premium to the offer price), well above the offer price—an indication of strong capital market recognition of the Company's growth potential. The active trading and high investor enthusiasm further corroborate the market's firm confidence in the consumer healthcare services sector and the Company's core value.Possessing a Large Customer Base with Continuously Improving ProfitabilityAs the third-largest provider of private mid- to high-end healthcare service in China, Distinct Healthcare has always adhered to its patient-oriented core principle, placing patient well-being at the forefront. This approach has enabled the Company to gradually build a large and high-quality patient base, leading the industry in both user scale and return rate.From 2022 up to the eight months ending 31 August 2025, the total number of patients served by its healthcare institutions in China rose from 162,393 to 212,180, and the total number of paid patient visits of its healthcare service institutions and tele-healthcare service platform grew from 529,829 to 642,132.Patient loyalty has continued to rise, with the patient return rate steadily climbing. In 2022, 2023, 2024 and the eight months ended 31 August 2025, the patient return rates reached 75.7%, 78.2%, 80.0% and 82.7%, respectively. This robust growth is a strong testament to the market and patients' high recognition of Distinct Healthcare's service quality.Leveraging its large and high-quality customer base and the advantages of its standardized medical services, Distinct Healthcare has achieved steady business growth "without relying on medical insurance subsidies or excessive marketing expenditure". Financial data shows the Company's total revenue increased steadily from RMB473 million in 2022 to RMB959 million in 2024, doubling its revenue in two years and achieving a compound annual growth rate (CAGR) of 42.3%, demonstrating strong growth momentum.In terms of profitability, the Company achieved a critical milestone by turning profitable in 2024, with an adjusted net profit of RMB10.7 million. This represents a qualitative leap from scale-driven growth to profitability-driven growth.Strong Line-up of Cornerstone Investors and Clear Strategic Plan Support High-Quality DevelopmentDistinct Healthcare has attracted a strong roster of cornerstone investors in this IPO, including Health Vision, Kingmed Diagnostics, Mininglamp Technology, and Galaxy Dynasty. Together, they subscribed for a total of approximately HK$90.7876 million. The active participation of these renowned, high-quality institutional investors fully reflects their high recognition of Distinct Healthcare's core competitiveness, business model, and future development prospects, and will also provide powerful resource support and brand endorsement for the Company's subsequent development, helping it to further expand its industry influence.Regarding the use of IPO proceeds, Distinct Healthcare has formulated a clear strategic plan to ensure the proceeds are effectively deployed to support the Company's high-quality growth. Approximately 35% of the net proceeds will be allocated to digitalization and intelligent upgrades. By building a professional talent pool for medical AI applications, establishing strategic partnerships with leading research institutions and technology companies and making external procurements, while leveraging internal IT and data technology departments to iteratively optimize existing IT systems, the Company will deploy advanced AI technologies, optimize medical service workflows and enhance diagnostic efficiency as well as operational effectiveness.Approximately 30% of the net proceeds will be used for service network expansion and upgrades, primarily focusing on enhancing the diagnostic environment and equipment at existing medical service institutions. It will also advance the layout of new institutions, including relocating an existing institution in Shenzhen and establishing new institutions in key cities such as Hangzhou and Shanghai, thereby further expanding and improving service coverage in key domestic regions.Approximately 25% is earmarked for strategic mergers and acquisitions, acquire high-performing medical service institutions with strong synergies in first-tier and new first-tier cities when suitable opportunities arise, aiming to rapidly expand market share and strengthen regional competitiveness. The remaining approximately 10% will be used as working capital and for general corporate purposes, providing stable financial support for daily operations and business expansion.This clear strategic roadmap not only charts a clear course for the Company's future growth, effectively enhancing its core competitiveness and sustainability, but will also further reinforce its leading position in China's private mid-to-high-end healthcare sector. It will help propel the Company to new heights, achieving its long-term goals of scaled and high-quality development.This successful listing on HKEX represents a significant milestone in Distinct Healthcare's development journey, marking its official entry into a new phase driven by both "capital and industry". It will further elevate the Company's brand influence and financing capabilities, injecting powerful momentum for its future growth.Moving forward, Distinct Healthcare will remain true to its founding aspirations, staying focused on the mid-to-high-end healthcare services segment. It will continue to enhance medical service quality and patient experience, further unlock its growth potential and deliver sustainable long-term returns to its shareholders. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Muyuan Foods Makes Hong Kong Debut Today: Strong Cornerstone Investor Backing Fuels Rapid Earnings Growth, Embarking on New Journey of Internationalization

HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – On 6 February, Muyuan Foods Co., Ltd. ("Muyuan Foods" or the "Company", Stock Code: 2714.HK), a global leader in the pork industry, officially listed on the Main Board of The Stock Exchange of Hong Kong Limited today, marking the beginning of a new chapter in the Company's international development.Powerful Cornerstone Investors Underscore Muyuan’s Industry LeadershipFor this Hong Kong IPO, Muyuan Foods successfully attracted a prestigious lineup of cornerstone investors, including Charoen Pokphand Foods, Wilmar International Limited (Wii Pte. Ltd. and HPRY), Sinochem Hong Kong, Hong Kong Henan AgriInternational, FIL Investment, RBC Global Asset Management (Asia) Limited and Ping An Life Insurance Company of China, Ltd., and other renowned institutions—14 in total—with combined subscription amounting to US$685 million. This formidable cornerstone investor group not only provides the Company with stable financial support but also brings abundant industrial resources and an international perspective, laying a solid foundation for its subsequent global expansion and valuation enhancement.As a technology-driven pork industry leader, Muyuan Foods has deep expertise cultivated over many years in the industry and has established a uniquely advantageous vertically integrated business model. Its operations comprehensively cover the entire pork industry chain, including hog breeding, hog farming, feed production, as well as slaughtering and meat production. Leveraging synergistic advantages across the entire chain, the Company has steadily maintained its leadership position in the hog farming industry.According to statistics from Frost & Sullivan, since 2021, measured by hog production capacity and hog sales volume, Muyuan Foods has become the world's largest hog farming enterprise. Its hog sales volume has ranked first globally for four consecutive years, solidifying its position as the industry leader. In terms of market share, the Company's global market share steadily increased from 2.6% in 2021 to 5.6% in 2024. As of 2024, this market share already exceeded the combined market share of the world's second to fourth largest participants in the hog farming industry, further widening the gap with peers and continuously highlighting its core competitiveness.Steady Earnings Growth Maintained; Active Overseas Market Expansion Strengthens CompetitivenessRelying on its full industry chain layout and efficient operational management, Muyuan Foods has maintained steady earnings growth in recent years, with profitability continuously improving, demonstrating the Company's operational resilience through solid business data. Data shows that the Company's revenue scale grew steadily from RMB124.826 billion in 2022 to RMB137.947 billion in 2024. Net profit surged significantly from RMB14.933 billion in 2022 to RMB18.925 billion in 2024, indicating remarkable growth and continuously optimized profitability. Entering 2025, the Company's growth momentum further accelerated. In the first nine months of 2025, the Company achieved operating revenue of RMB111.790 billion, a year-on-year increase of 15.5%, and realized a net profit of RMB15.112 billion, a substantial year-on-year increase of 34.4%. The double-digit growth in both revenue and net profit fully demonstrates the Company's strong development momentum and favorable profit outlook.While consolidating its leading position in the domestic market and achieving rapid self-development, Muyuan Foods has consistently anchored its global development strategy, actively expanding into overseas markets. Using the export of technology and equipment as a key approach, it empowers the upgrading of the global hog farming industry and builds an international farming ecosystem. In 2024, the Company entered into a deep strategic partnership with BAF Vietnam Agriculture, providing services including hog house design, biosecurity management, odor control solutions and smart hog farming to help its partner optimize farming efficiency, reduce operational costs, and practice environmentally responsible farming.The smooth progress of this cooperation marks a crucial first successful step for Muyuan Foods in its global layout, accumulating valuable experience for subsequent overseas market expansion. On the other hand, leveraging the vast potential of overseas markets, Muyuan Foods will further achieve optimized resource allocation and efficient synergy on a global scale, continuously broadening its corporate growth boundaries and diversifying profit sources, thereby solidifying its core advantages and enhancing comprehensive competitiveness.Overall, the successful listing in Hong Kong not only signifies that Muyuan Foods has formally entered a new stage of internationalized development, establishing an important bridge connecting global capital and resources, but also indicates that the Company's operational management level, industry competitiveness, and development potential have gained broad recognition from the international capital market. In the future, Muyuan Foods will seize this listing opportunity, adhere to the philosophy of technology-driven and green development, continue to deepen its involvement in the entire pork industry chain, constantly strengthen its core competitiveness, steadily advance its global layout, further consolidate its position as the global leader in the hog farming industry, and open up broader growth space. Its future development is worthy of market anticipation. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Everest Medicines Announces China NMPA Approval of VELSIPITY(R) for Adults with Moderately to Severely Active Ulcerative Colitis

HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – Everest Medicines today announced that China's National Medical Products Administration (NMPA) has approved VELSIPITY(R) (etrasimod arginine tablets) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.UC is a chronic, relapsing, non-specific inflammatory bowel disease. In China, the incidence and prevalence of UC are accelerating, with a clear trend toward younger patients. The patient population is projected to increase from approximately 0.98 million in 2025 to 1.50 million by 2031.There remains a critical need for therapies that offer sustained and comprehensive disease control.As a next-generation selective S1P receptor modulator, VELSIPITY(R) offers the potential for rapid onset of action, and long-lasting clinical remission and mucosal healing through an oral, once-daily regimen for adult patients with moderately to severely active UC.The approval was based on results from the Asian multicenter Phase 3 ENLIGHT UC study (ES101002) and the global ELEVATE UC Phase 3 program (ELEVATE UC 52 and ELEVATE UC 12). The ENLIGHT UC study is the largest Phase 3 trial of moderately to severely active UC in Asia completed to date, with 340 eligible subjects randomized to treatment with VELSIPITY(R) or placebo. The study results showed that, VELSIPITY(R) demonstrated statistically significant and clinically meaningful improvements across all primary and secondary efficacy endpoints during both the 12-week induction period and the 40-week maintenance period. The safety profile of VELSIPITY(R) was consistent with previous studies, with no new safety signals observed. The study confirms the efficacy and safety of VELSIPITY(R) in this population, with results published in The Lancet Gastroenterology & Hepatology.From a clinical value perspective,VELSIPITY(R) is a once-daily oral therapy with rapid onset of action, strong mucosal healing efficacy, and a favorable safety profile. Prof. Chen Minhu, Academic Leader and Chief Expert of the Department of Gastroenterology at The First Affiliated Hospital of Sun Yat-sen University noted that UC is rapidly increasing in China and follows a relapsing course that significantly impairs quality of life and places a substantial burden on both patients and the healthcare system. Achieving mucosal healing is a widely recognized treatment goal in clinical guidelines, as it improves symptom control, reduces relapse risk, and supports long-term disease management.“UC treatment in China has long faced limited efficacy, high relapse rates, safety concerns, and inconvenient dosing. Despite available biologics and small-molecule therapies, unmet clinical needs persist,” said Prof. Wu Kaichun of the First Affiliated Hospital of AFMU, principal investigator of VELSIPITY(R)’s Asian clinical trial. “Its approval represents an important milestone and validation, providing patients with a novel treatment option and advancing UC management.”“Autoimmune diseases have long-term impacts on patients worldwide, with significant unmet clinical needs persisting both in China and globally,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “The approval of VELSIPITY(R) underscores the clinical value of innovative therapies for UC and reflects Everest Medicines’ sustained commitment to advancing drug development in line with international R&D standards. We look forward to expanding our global reach and providing patients with broader access to innovative treatment options.”“Its approval in China addresses a critical unmet medical need and introduces a novel oral therapy promoting deep mucosal healing,” said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “We are committed to rapidly commercializing VELSIPITY(R) and working toward its inclusion in the National Reimbursement Drug List to further expand patient access and affordability, benefiting more patients across China.”The clinical value of VELSIPITY(R) has been recognized in leading international clinical guidelines. Following its inclusion in the American Gastroenterological Association (AGA) Clinical Practice Guideline in December 2024 as a first-line treatment for ulcerative colitis , VELSIPITY(R) was also included in the American College of Gastroenterology (ACG) Clinical Guideline Update in June 2025, with strong recommendations supporting its use for both induction and maintenance of remission in patients with moderately to severely active UC. In 2024, VELSIPITY(R) was included in the Catalogues of Guangdong Province on Drugs and Medical Devices from Hong Kong and Macao in Urgent Clinical Use in Nine Mainland Municipalities of the Guangdong-Hong Kong-Macao Greater Bay Area, making it available at designated hospitals across the region. The localized production project for VELSIPITY(R) was launched at the Jiashan manufacturing site in March 2025, supporting its future commercialization in China.The successful approval of VELSIPITY(R) further strengthens Everest Medicines’ product portfolio in the field of autoimmune diseases and also forms a critical part of the 2030 strategy of the Company. This strategy is built on a dual-engine model of business development partnerships and in-house R&D, aiming to generate predictable value through commercialization while building long-term growth momentum through sustained innovation, thereby supporting pipeline continuity and sustainable development.The Company has established a portfolio of three commercial products and continues to develop a fully integrated commercial platform covering the entire product lifecycle.The Company targets annual revenue exceeding RMB10 billion by 2028, and RMB15 billion by 2030 (including approximately RMB9 billion from the existing pipeline and approximately RMB6 billion from newly in-licensed assets). Revenue is expected to grow at a compound annual growth rate (CAGR) of over 50% from 2025 to 2030 and to remain above 15% thereafte.Over the same period, the number of commercial products is expected to exceed 20, including NEFECON(R), VELSIPITY(R), XERAVA(R), Lerodalcibep and MT1013.Industry observers widely expect VELSIPITY(R) to become Everest's next blockbuster product, with analysts projecting peak sales of up to RMB 5 billion. As VELSIPITY(R) realizes its commercial potential, Everest's revenue mix and growth trajectory are expected to strengthen further. Looking ahead, Everest Medicines will continue to focus on therapeutic areas with significant unmet clinical needs. Leveraging its established commercialization capabilities and in-house R&D, the company aims to accelerate the launch of innovative therapies with global competitiveness, drive sustainable growth, and create greater health value for patients and society.  Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Spritzer Celebrates Continued Excellence with Dual Recognition at Putra Brand Awards 2025 and Superior Taste Award 2025

The accolades underscore Malaysia’s leading mineral water brand’s international achievements in their consistent pursuit of quality, excellence and industry leadershipKUALA LUMPUR, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) - Spritzer Berhad (“Spritzer” or “the Company”), Malaysia’s leading natural mineral water brand started the year on a strong note with a repeat of the annual recognition by two prestigious platforms, the Putra Brand Awards 2025 and the Superior Taste Award 2025. These achievements, their 10th and 15th recognition for each award respectively, reinforce Spritzer’s continued efforts and commitment to excellence, innovation and uncompromising standards in delivering high-quality natural mineral water locally and internationally.Spritzer Wins the Gold at the Putra Brand Awards 2025Spritzer was awarded the Gold Award in the Beverage – Non-Alcoholic category at the Putra Brand Awards (PBA) 2025, marking its 10th impressive win in the category, further reaffirming its status as Malaysia’s most trusted natural mineral water brand. The Putra Brand Awards are uniquely consumer-driven, with winners selected solely by Malaysian consumers as the judge of brand excellence across 30 categories. As a genuine reflection of the brand’s enduring consumer affinity, market confidence and brand relevance, the accolade is particularly meaningful.Spritzer’s win as the only mineral water brand amidst other well-loved global beverage brands in Malaysia highlights Spritzer’s competitiveness and firm standing in the national beverage landscape. The award was proudly accepted by Dr. Chuah Chaw Teo, Research and Development (R&D) Director of Spritzer, on behalf of the Company.“Winning the Putra Brand Awards for the 10th year affirms our consistent efforts to keep improving over the years,” said Dr. Chuah. “Behind this recognition lies years of disciplined research and development (R&D), stringent quality control, and continuous improvement across our operations and customer touch points. Our priority has always been to safeguard the integrity of our natural mineral water while innovating responsibly to meet the evolving needs of consumers and businesses.”Photo 1 and 2: Spritzer celebrates its Gold Award in the Beverage - Non-alcoholic Category at The Putra Brand Awards 2025A Superior Triumph in Taste GloballySpritzer’s product excellence was further validated internationally at the Superior Taste Award 2025, a globally respected certification conferred by the International Taste Institute in Brussels, Belgium known for its rigorous, professional sensory evaluation of food and beverage products. In 2025, Spritzer Natural Mineral Water secured the prestigious 3-Star Superior Taste Award for the 10th year, a milestone that continues to build on Spritzer’s 15-year legacy of recognition by the International Taste Institute.This long-term acclaim reflects the brand’s unwavering dedicated to delivering natural mineral water of exceptional quality and taste. It reaffirms Spritzer’s strong product capabilities, from taste profile to mineral composition, and its commitment to upholding stringent international benchmarks, further cementing its dominance in Malaysia’s bottled water sector and boosting consumer assurance across local and global markets.Established in 2005, the International Taste Institute is known for its independent, blind tasting methodology, conducted by a panel of over 250 world-class chefs and sommeliers from more than 20 countries worldwide. Products are assessed against strict sensory criteria and only those achieving a score above 70% are certified with the Superior Taste Award, with distinctions awarded based on performance.Photo 2: Spritzer secured the prestigious 3-Star Superior Taste Award for the 10th year for Spritzer Natural Mineral WaterReinforcing Trust Across Markets and StakeholdersTogether, these two awards signify strong domestic consumer confidence and international endorsement of product quality. Backed by robust R&D processes, consistent quality management and a long-standing heritage rooted in nature, Spritzer continues to demonstrate reliability and leadership in the industry.Dr. Chuah concluded, “These speak to the trust that consumers place in us every day. Spritzer remains committed to protecting the purity of our source, strengthening our innovation pipeline, and continuing to deliver natural mineral water of the highest quality that Malaysians and global consumers can rely on.”Supported by its partners, customers, and dedicated team, the Company will continue to represent Malaysian quality on the global stage.For more high-resolution photos, please download them here.About SpritzerEstablished in 1989, Spritzer is a leading Malaysian bottled water brand, sourcing natural mineral water from a protected 430-acre rainforest in Taiping. Naturally filtered through underground rock layers for over 15 years, our water is enriched with essential minerals like Silica, known to support skin, bones, hair, and nails.Combining smart manufacturing with sustainable practices, Spritzer ensures every bottle meets the highest quality and safety standards. Our packaging is 100% recyclable and made from recycled materials, reflecting our commitment to environmental stewardship and a circular economy.Tested annually by SIRIM to be free from microplastics, Spritzer offers consumers trusted, natural hydration. Our diverse product range includes Natural Mineral Water, Original and Flavoured Sparkling Water, Distilled Water, and Fruit-Flavoured Beverages—crafted to suit every lifestyle and occasion.With a clear vision to become a fully circular brand by 2030, Spritzer leads the industry in innovation, quality, and sustainability.Spritzer — where nature, innovation, and sustainability come together in every bottle.For more information, visit www.spritzer.com.myFor media inquiries please contact:Imelia KyraAssociate Consultant, Narro CommunicationsE: imelia@narrocomms.comWinnie ChinHead of Public Relations, Spritzer BhdE: winniecgl@spritzer.com.my Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Eternal Beauty Holdings Limited and Lane Crawford Debut Landmark Fragrance, Further Expanding Footprint in High-Margin Niche Fragrance Market

HONG KONG, Feb 6, 2026 - (ACN Newswire via SeaPRwire.com) – Eternal Beauty Holdings Limited (“Eternal Beauty” or the “Group”) (Stock Code: 6883.HK), a pioneer in China’s beauty and fragrance industry, announced its first-ever collaboration with Lane Crawford, a premier luxury department store, to launch an exclusive boutique niche fragrance section at its Harbour City store in Tsim Sha Tsui. The collaboration aims to further advances the Group’s strategy focused on high-margin niche fragrance brands, strengthens its premium brand footprint through an elite retail network, and captures the growing profit opportunities in the niche fragrance for Chinese Mainland and Hong Kong markets.The zone brings together four international niche fragrance brands under the immersive concept of a "Luxury Niche Perfume Street" with European flair, featuring Atkinsons, Clive Christian, Memo Paris and SOLFÉRINO, each presented with its unique style and heritage. Clive Christian and SOLFÉRINO are making their debut in Hong Kong, offering a rare experience to local high-end consumers. By leveraging Lane Crawford’s premium retail network that reaches high-spending customers, the Group effectively enhances brand penetration in the Hong Kong market. This initiative successfully introduces the Group’s portfolio into a core upscale retail destination in Hong Kong, demonstrating the Group’s strengths in channel expansion and retail curation, while further solidifying its brand influence and long-term growth momentum in the niche fragrance portfolio.Brand Introduction:AtkinsonsThe 200-year-old British "Royal Fragrance House" reinvents the rebellion and elegance of 19th-century English gentlemen, transforming historical formulas into a modern, contemporary aura.Clive ChristianThe first exclusive collectors’ boutique in Hong Kong: Clive Christian is a luxury British perfume house that creates the world's finest perfumes. A legacy of British craftsmanship, unparalleled quality in concentration and complexity, unashamedly indulgent and luxurious presentation.Memo ParisMemo Paris is a Parisian fragrance house, see each fragrance as a travel note captured in scent. Preserve memory of a journey to unique destination. Memo Paris sketches a delicate, emotional map of the world: a universe where memories become scents.SOLFÉRINODebuting brilliantly in Hong Kong, SOLFÉRINO is born in Paris, France, the brand draws inspiration from the historic architecture of this City of Lights, showcases French elegance with exceptional craftsmanship and presenting Parisian audacity and creativity.Ms. Wendy Lau, Executive Director of Eternal Beauty and Chairman of the International Fragrance Association, said, “With over 40 years of industry experience, Eternal Beauty has cultivated sharp market vision, distinctive taste, and profound expertise. This enables the Group to accurately identify and introduce brands that align with market trends and carry strong profit potential into the Greater China market, which continues to demonstrate vigorous consumption upgrade momentum. We are thrilled to partner with Lane Crawford, an influential luxury department platform in Asia, to create this exclusive boutique niche fragrance section in Hong Kong’s core luxury shopping district, leveraging the Group’s strengths in niche fragrance brand management and retail channel development. This is not only an important step for the Group to deepen the niche fragrance market, but also a concrete manifestation of our niche fragrance brand expansion strategy. Moving forward, the Group will continue to explore collaborations with top-tier retail partners. By introducing more niche brands with high growth potential, it will strengthen its long-term growth momentum and enhance sustainable profitability in the fragrance market.”Hong Kong's fragrance market continues to benefit from the momentum of the emotional economy, demonstrating relatively resilient growth against the backdrop of a steady recovery in the overall retail sector. In December 2025, the value of total retail sales in Hong Kong increased by 6.6% YoY; according to market’s outlook reports, the total retail sales in Hong Kong are expected to grow by nearly 8% in 2026, reaching approximately HKD 410 billion, indicating a continued recovery in local consumer demand. Ms. Chole Lam, Executive Director and Chief Executive Officer of Eternal Beauty, said, “In recent years, experiential retail and emotional consumption have gradually emerged as new retail trends, with emotional value playing an increasingly significant role in consumer decision-making. The ability to establish emotional resonance with consumers is becoming an important direction for brand expansion and product innovation. Emerging consumption segments, represented by high-end and niche fragrances, are more being regarded as categories that carry emotional value and lifestyle propositions, highlighting their growth potential in the retail recovery process.”Eternal Beauty has established an omni sales channel network over 400 cities across Chinese Mainland, Hong Kong and Macau. The cooperation with Lane Crawford is an important part of the Group’s retail channel strategy, aiming to enhance the consumer experience and sales conversion by leveraging the prime location and high customer traffic of the premium department store.Photo CaptionEternal Beauty and Lane Crawford debut landmark niche fragrance zone, bringing together four international niche fragrance brands under the concept of a "Luxury Niche Perfume Street". The zone immersively showcasing four distinctive and heritage-rich brands: Atkinsons, Clive Christian, Memo Paris, and SOLFÉRINO.Please download more high-resolution photos via link:https://drive.google.com/drive/folders/1nzCNkjNqd9f5RDCub3vmLpoesN52MJbS?usp=sharingAbout Eternal Beauty Holdings LimitedEternal Beauty Holdings Limited is the largest perfume group (apart from brand-owner perfume groups) in China (including Hong Kong and Macau) in terms of retail sales in 2023. It primarily sells and distributes products procured from third-party brand licensors, and deploys market for these brand licensors, offering such services as brand management, and designing and implementing customized market entry and expansion plans for their brands. The Group boasts large and diversified brand portfolios that include not only perfumes, but also color cosmetics, skincare products, personal care products, eyewear and home fragrances. As at 30 September 2025, it conducted product distribution and market deployment for a total of 74 external brands, including Hermès, Van Cleef & Arpels, Chopard, Albion and Laura Mercier, with products in different pricing tiers and of versatile features that meet the differentiated demands of consumers in Chinese Mainland, Hong Kong and/or Macau. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

GIC Private Limited initiated a stake in Ascletis Pharma (01672) by 64,128,000 shares at a price of HKD 12.18 per share

HONG KONG, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) – According to the disclosure of interests information released by the Hong Kong Stock Exchange, GIC Private Limited made its equity investment in Ascletis Pharma by acquiring 64,128,000shares at a price of HKD12.18per share, involving a total consideration of approximately HKD781.08million (equivalent to approximately USD100.01 million). Following the transaction, GIC's shareholding in Ascletis Pharma amounted to 64,128,000shares, representing a shareholding percentage of 6.42%, marking GIC's initial entry into the company's shareholder base. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HKTDC to host world’s largest one-stop jewellery marketplace

HONG KONG, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) – Organised by the Hong Kong Trade Development Council (HKTDC), the world’s largest one-stop jewellery marketplace will return in early March under its proven “Two Shows, Two Venues” format. The 12th Hong Kong International Diamond, Gem & Pearl Show will take place from 2 to 6 March at AsiaWorld-Expo and will feature a wide range of jewellery raw materials. Also, the 42nd Hong Kong International Jewellery Show will be held from 4 to 8 March at the Hong Kong Convention and Exhibition Centre and will showcase finished jewellery pieces.Jenny Koo, Deputy Executive Director of the HKTDC, said: “This year’s twin jewellery shows bring together some 4,000 exhibitors from over 40 countries and regions, with 70% coming from outside Hong Kong. Exhibitor participation from Brazil, United Arab Emirates and India has expanded, and Uzbekistan joins for the first time. The HKTDC presents the world’s largest one-stop jewellery marketplace to highlight Hong Kong’s status as an international trade capital and jewellery sourcing hub.”In reviewing the global jewellery market, Hong Kong’s export volume of premium jewellery to ASEAN recorded a 51% increase, while exports to the United Kingdom, Australia and Switzerland grew year-on-year by 36%, 28% and 10% respectively.Over 40 themed pavilions, including a new Hard Pure Gold PavilionThe twin shows attract strong global industry support, with exhibitors participating from over 40 regional and industry pavilions. Participating regions include Chinese Mainland, Taiwan, India, Israel, Korea, Myanmar, Singapore, Sri Lanka, Thailand, Uzbekistan, Belgium, Germany, Italy, Spain, Türkiye, Brazil, Colombia, Mexico and the United States, etc.The World Gold Council debuts the Hard Pure Gold Pavilion, featuring a total of 11 exhibitors from Chinese Mainland, showcasing innovative gold craftsmanship to the global market. The pavilion aims to leverage the fairs as a springboard for international expansion.The Hong Kong Watch Manufacturers Association Ltd will participate as a pavilion for the first time, while the Zhushan Turquoise pavilion from Hubei will also make its debut. Other returning participants include the Tanzanite Foundation, the International Colored Gemstone Association (ICA), the Asia Pacific Creator Association, and the Asia Jewellery Culture Design and Crafts Association. The Hong Kong Jewellery & Jade Manufacturers Association will once again join forces with the Italian Exhibition Group (IEG) to present advanced jewellery manufacturing equipment and technologies.International brands in the spotlightThe Hall of Fame at the Hong Kong International Jewellery Show makes a highly anticipated return this year with more than 40% expansion in scale. It will welcome renowned international jewellery brands and help enhance global brand exposure. Turkish diamond jewellery brand Zen Diamond (Booth: CEC 3B-C12) presents diamond ring collections featuring exquisite cutting techniques. At the Hall of Extraordinary, Hong Kong exhibitor Continental Diamond Company (Booth: CEC GH-C07) showcases an 18K white and rose gold ring set with blue and light pink diamonds. Another Hong Kong exhibitor, Unique Brilliant Ltd (Booth: CEC GH-C13), unveils a necklace and earring set, the rubies display the coveted “pigeon blood red” colour.Oriental Aesthetics showcases cultural heritage craftsmanshipThis year’s shows will feature numerous jewellery pieces inspired by Asian culture and heritage. Chinese Mainland exhibitor, Guangdong JIABAO Pavilion Jewellery (Hong Kong) Company Ltd (Booth: CEC GH-A16) presents an 18K gold, handmade filigree butterfly brooch, made with national intangible heritage craft, with each piece taking over four months to complete. Another Chinese Mainland exhibitor, Shenzhen Meifei Precious Metals Co Ltd (Booth: CEC 3E-E02), brings a “Palatial Modern Chinese Style” jewellery series incorporating six traditional gold techniques, blending heritage craftsmanship with modern jewellery design.In recent years, hard pure gold technology has gained strong momentum in Chinese Mainland. Its high purity and enhanced hardness enable lighter, more durable designs with modern aesthetics. A seminar organised by the World Gold Council will examine the latest developments in the global gold market and hard pure gold technology.During the fairs, a series of events spotlighting Oriental aesthetics in jewellery will be staged. Hong Kong International Fashion Chuk Kam Jewellery Design Competition 2026, organised by the Jewellers’ and Goldsmiths’ Association of Hong Kong Limited, encourages designers to create commercially viable and culturally rich gold jewellery for young consumer markets in ASEAN and the Middle East. Its award presentation ceremony will be held during the fairs.In addition, the inaugural International Fei Cui Jewellery Design Competition 2026, organised by the Hong Kong Jade Association, will also host its awards presentation during the fairs.Creative design sets the trendInnovative and trend-driven products help the industry stand out. Austy Lee Company Ltd (Booth: CEC 1E-F32) introduces bangles inspired by zebra patterns for the Year of the Horse. Designer Galleria welcomes new exhibitor Zheng Hong Collective (Booth: CEC 1CON-067A), featuring a brooch whose movable wings and tail sway with the wearer.The 27th Hong Kong Jewellery Design Competition, themed “Pure Elegance – Natural Beauty”, returns to nurture creative talent. Local students and industry professionals interpret the beauty of nature and their design stories through their creations, highlighting the diverse facets of jewellery design. Winning designs will be announced during the fairs.Rare treasures dazzle across both showsAs always, the twin shows offer buyers an outstanding selection of antique and rare jewellery. At the Hong Kong International Jewellery Show, Hong Kong exhibitor Baroque Antique & Jewellery Limited (Booth: CEC CH-F13) presents a 1970s Buccellati pink sapphire suite, while World Coins Co., Ltd. (Booth: CEC CH-N12) showcases a 19th-century Italian bi-colour enamel diamond piece preserved in its original box for over 100 years. At the Hong Kong International Diamond, Gem & Pearl Show, German exhibitor Caram e.K. (Booth: AWE 8-F05) features an 18.98-carat AGL-certified natural pink sapphire, while Canadian exhibitor Korite Ammolite Ltd. (Booth: AWE 8-F35) displays an 18K gold AA-grade ammolite and diamond necklace.The Hong Kong International Jewellery Show will also host a seminar titled “The Origins of Style: Tracing the Imprint of Time and Craftsmanship.” This seminar will invite British historian and jewellery authority Dr. Jack Ogden to speak. He will provide an in-depth analysis of the evolution of jewellery craftsmanship and changes in aesthetic tastes across different eras.Over 20 forums on hot topics including AI and digital marketingMore than 20 seminars and networking sessions will be held, covering industry trends, digital marketing and jewellery technologies. A session will examine how artificial intelligence moves from design to commercialisation to drive the development of the jewellery industry. There will also be seminars where influencers share how to leverage e-commerce platforms to enhance jewellery brand visibility, boost sales, and share practical experience, to help the industry accelerate the integration and synergy between online and offline channels.Business opportunities and industry exchangeThe exhibition attracts major international jewellery retail chains, as well as high-end, affordable luxury, and designer jewellery brands from around the world for sourcing. It creates business opportunities for both buyers and sellers while fostering industry exchange.The HKTDC has partnered with the Hong Kong Tourism Board and local enterprises to provide exclusive buyer privileges. These offers include dining, air tickets, and hotels, enabling buyers to enjoy Hong Kong’s unique charm while attending the fairs. The HKTDC will arrange free shuttle bus services between AsiaWorld-Expo and urban areas (including the Hong Kong Convention and Exhibition Centre in Wan Chai). For details, please refer to the fair’s official website.Combining online and offline services to facilitate sourcingThe shows use the EXHIBITION+ hybrid format. In addition to on-site procurement, the HKTDC’s AI-powered “Click2Match” will provide online business-matching for exhibitors and buyers from 23 February to 13 March. On-site buyers can use "Scan2Match" to scan exhibitors’ QR codes and continue discussions with exhibitors online during or after the show. To ease the buyer admission process, the HKTDC Marketplace App and the official websites of the two shows provide online verification functions. Buyers need only register through these platforms and upload a photo and valid identification to obtain a verified eBadge for direct entry, greatly reducing queuing times for onsite registration and verification and enhancing sourcing efficiency.Photo download: https://bit.ly/4ayrcAoAttending the press conference to introduce the twin jewellery shows today (5 February): Jenny Koo, HKTDC Deputy Executive Director (centre), Winston Chow, Chairman, HKTDC Jewellery Advisory Committee (left) and Kent Wong, Chairman, HKTDC Hong Kong International Jewellery Show and HKTDC Hong Kong International Diamond, Gem and Pearl Show Fair Organising Committee (right)Jenny Koo (front row, third left) took a group photo with members of the organising committee of the HKTDC Hong Kong International Jewellery Show and the Hong Kong International Diamond, Gem and Pearl Show, joined by celebrity guestArtist Hera Chan (third right) led a group of models to exhibit exquisite jewellery pieces from the showsArtist Hera Chan wore a natural Myanmar jadeite set presented by exhibitor On Tung Company. The exquisite ensemble featured a translucent emerald green jadeite and diamond necklace, ring, and earrings, showcasing a regal and graceful designThe phoenix features in traditional Chinese wedding jewellery, symbolizes auspiciousness and good fortune. Exhibitor Lao Feng Xiang Jewellery Hong Kong Limited presented a "China chic" wedding collection imbued with Oriental charm, crafting accessories that embody the imperial elegance of a royal court for womenWebsites Hong Kong International Jewellery ShowExhibition websitehttp://hkjewelleryshow.hktdc.com/tcShuttle bus detailshttps://www.hktdc.com/event/hkjewellery/tc/travel-to-fairground-hkcecActivity listhttps://www.hktdc.com/event/hkjewellery/tc/intelligence-hub  Hong Kong International Diamond, Gem & Pearl ShowExhibition websitehttp://hkdgp.hktdc.com/tcShuttle bus detailshttps://www.hktdc.com/event/hkdgp/tc/travel-to-fairground-aweActivity listhttps://www.hktdc.com/event/hkdgp/tc/intelligence-hubHKTDC Media Room: https://mediaroom.hktdc.com/enMedia enquiriesPlease contact HKTDC’s Communication & Public Affairs Department:Winnie KanTel: (852) 2584 4055Email: winnie.wy.kan@hktdc.orgKaty WongTel: (852) 2584 4524Email: katy.ky.wong@hktdc.orgJane CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Everest Medicines Announces Exclusive License Agreement with Micot to Commercialize MT1013

Shanghai, January 5, 2026 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive license agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd. (“Micot”) to commercialize MT1013, the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism (SHPT) as its leading indication, in China and Asia-Pacific (excluding Japan).According to the agreement, Everest Medicines will pay Micot an upfront payment of RMB 200 million and potential regulatory and commercial milestone payments of up to RMB 1,040 million. MT1013 has entered Phase III clinical trial in China and the relevant development expenses will be covered by Micot. The strategic collaboration is expected to complement Everest Medicines’ existing renal pipeline and drive operating synergies, further strengthen the Company’s commercial product portfolio, and solidify its leading position in renal and autoimmune diseases in Asia, which are key therapeutic areas of focus. The collaboration will also expand the Company’s nephrology portfolio from IgA nephropathy to a broader range of chronic kidney diseases (CKD).MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide internally developed by Micot. The Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology (ASN) Annual Meeting. MT1013 uniquely combines the calcium-sensing receptor (CaSR) and the osteogenic growth peptide (OGP) receptor, addressing imbalances in parathyroid hormone (PTH), calcium, and phosphate metabolism. This innovative dual mechanism allows MT1013 to control SHPT and related bone metabolism disorders at the source, and to actively promote bone formation and repair through direct activation of osteogenic pathways, representing a therapeutic innovation shift from indirect inhibition of bone resorption to active stimulation of bone formation.Clinical studies have demonstrated that MT1013 acts rapidly, with strong and durable efficacy, and has a favorable safety profile in patients with CKD on maintenance hemodialysis with SHPT. It has shown potential advantages over current therapies in achieving comprehensive endpoints, including control of intact parathyroid hormone (iPTH), serum calcium, and phosphate levels, as well as improving calcium-phosphate balance and offering potential cardiovascular benefits. MT1013 is currently being evaluated in a Phase III clinical trial in China for this patient population, with over 50% of the target enrollment already achieved. SHPT is one of the most common and serious complications in patients with CKD. It causes disturbances in calcium and phosphate metabolism, elevated PTH levels, bone disorders, and vascular calcification, which substantially increase the risk of fractures, cardiovascular events, and mortality. SHPT is therefore an important factor influencing outcomes and prognosis in patients with CKD. With the global prevalence of CKD continuing to rise, the unmet medical need for effective SHPT therapies is also growing. Data indicate that the global population of patients with CKD has increased from 905.2 million in 2019 to 1.0655 billion in 2024 and is projected to exceed 1.2 billion by 2030 and 1.5 billion by 2035. Over the same period, the number of patients with SHPT has also continued to rise and is expected to reach approximately 189.9 million by 2030 and 221.7 million by 2035, highlighting a substantial and growing unmet medical need.“We are very pleased to collaborate with Micot. As the global burden of chronic kidney disease continues to rise, addressing patients’ unmet needs remains a top priority.,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “MT1013 represents an innovative asset with the potential to expand treatment options for patients with secondary hyperparathyroidism. Through this partnership, we aim to leverage our expertise in autoimmune-related kidney disorders while broadening our renal portfolio to include additional diseases, including glomerulonephritis and complications associated with dialysis. Looking ahead, we will jointly advance the development and commercialization of MT1013 to bring innovative treatment options to a broader population of patients with kidney disease.”“We are delighted to enter into this strategic collaboration with Everest Medicines. Everest’s deep expertise in nephrology and established commercialization capabilities make it an ideal partner to bring MT1013 to patients in China and beyond,” said Dr. Bing Wang, Founder, Chairman, and President of Micot. “MT1013 is a pivotal achievement of our peptide technology platform and a key milestone in our commitment to advancing innovative therapies for chronic diseases. Its unique dual-targeting mechanism has the potential to deliver meaningful advances in the treatment of secondary hyperparathyroidism. We look forward to working closely with Everest to accelerate clinical development and commercialization, address critical unmet medical needs, and advance care for patients with kidney disease.”MT1013 has completed its pivotal Phase II clinical trial, which demonstrated robust and sustained iPTH suppression in patients with SHPT undergoing maintenance hemodialysis. In head-to-head comparisons with etelcalcetide, MT1013 showed advantages in comprehensive disease management, achieving higher rates of simultaneous control of iPTH, serum calcium, and phosphate, as well as greater reductions in phosphate and the cardiovascular risk marker FGF-23. Over 52 weeks of treatment, MT1013 also resulted in significant improvements in bone mineral density and bone metabolism markers, supporting the potential clinical benefits of its unique dual-target mechanism in both disease management and bone health.Building on these positive results, the Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology Annual Meeting. MT1013 has now advanced into a confirmatory Phase III clinical trial in China with cinacalcet as the active comparator. The Phase III study has been launched across more than 100 sites nationwide, aiming to enroll approximately 424 patients, specifically targeting individuals with SHPT undergoing maintenance hemodialysis due to chronic kidney disease.About MT1013MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism as its leading indication and is planned to expand into additional indications including Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) with Osteoporosis and SHPT not on Dialysis. MT1013 completed its Phase II clinical trial (MT1013-II-C01) for the treatment of SHPT in May 2025 and has entered a Phase III clinical trial using Cinacalcet as the active comparator.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.About MicotShaanxi Micot Pharmaceutical TechnologyCo., Ltd.("Micot") was founded in Xi’an in January 2007 and now operates in China (Xi’an, Suzhou, Beijing, Shanghai, Hong Kong) and the U.S. An R&D-driven innovator, Micot develops dual- and multi-functional peptide drugs for cardiovascular/cerebrovascular and metabolic diseases to address unmet clinical needs.As the proposer, implementer, validator, and developer of the bispecific peptide concept, Micot stands as a premier platform for peptide drug R&D. It utilizes a unique mechanism for screening multi-target peptide therapeutics and possesses platform-based R&D capabilities to develop both First-in-class and Best-in-class candidates.Currently, Micot has a robust reserve of new drug candidates, with seven proprietary innovative pipelines currently in clinical stage: one in Phase III, three in Phase II, and three in Phase I. Dedicated to creating breakthrough medicines and saving lives, Micot strives to address unmet clinical needs and leverages scientific innovation to safeguard human health. For more information, please visit the website: www.micot.cn.Forward-Looking StatementsThis news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com